• SMi Source has 1346 microlearning topics and 90 lessons when searching for Cardiovascular

  • Lessons

    Click to learn more

    Cardiovascular Primer

    Atherosclerosis: Heart Failure

    Atherosclerosis: Pathophysiology

    Diabetes: Epidemiology

    Cardiovascular: Diabetes and Metabolic Syndrome

    Diabetes: Introduction to Incretin

    Atherosclerosis: Cholesterol Metabolism, Lipoproteins, and Residual Risk

    Anticoagulation: Health Economics and Outcomes Research

    Mechanical Ventilation: Practice

    Diabetes: Introduction to Clinical Trial Design

    Atherosclerosis: Treatment

    Lupus: Clinical Presentation

    Cardiovascular: Venous Thromboembolism Pathophysiology and Treatment

    Diabetes: Basis for Some Measures Used in Studies

    Reproduction: Hypogonadism Treatment of Males

    Diabetes: Obesity Trends Among U.S. Adults (BRFSS)

    Cardiovascular: Atrial Fibrillation

    Cardiovascular: Venous Thromboembolism

    Cardiovascular: Platelet Biology

    Cardiovascular: Acute Coronary Syndrome

    Cardiovascular: Interventional Therapy

    Cardiovascular: Atrial Fibrillation Pathophysiology

    Cardiovascular Primer: Anatomy and Physiology of the Circulatory System

    Cardiovascular Primer: Anatomy and Physiology of the Circulatory System

    Atherosclerosis: Lipid Lowering Agents

    Cardiovascular: Hypertension

    Cardiovascular: Hyperlipidemia

    Anticoagulation: Thienopyridines

    Cardiovascular: Heart Failure

    Binge Eating Disorder

    Anticoagulation: Antiplatelet Drug Therapy

    Diabetes: Pathology of Complications

    Reproduction: Hypogonadism Pathophysiology

    Cardiovascular: Myocardial Infarction

    Cardiovascular: Cancer VTE

    Lysosomal Storage Disorders: Hunter Syndrome

    Cardiovascular: Coronary Artery Bypass Grafting

    Stroke: State

    Stroke

    Diabetes: Type 2 Pathophysiology

    Anticoagulation: Studies and Registries

    HIV: Therapeutic Regimens

    Immunology: Therapeutic Immunology

    Anticoagulation: Treatments II

    Anticoagulation: Novel Oral Anticoagulants

    Alzheimer's Disease: Biomarkers

    Major Depressive Disorder: Treatment

    Multiple Sclerosis: Pathogenesis and Clinical Symptomology

    Multiple Sclerosis: Diagnosis and Prognosis

    Biotech: Monoclonal Antibodies

    Psoriasis: Treatments

    Drug R&D: Toxicology Applications

    Alzheimer's Disease: Epidemiology of Dementia

    Genetics: Introduction

    Edoxaban

    Schizophrenia

    Immunology: Autoimmune Disorders and Hypersensitivity

    Alzheimer's Disease: Treatment

    Cardiovascular: Pulmonary Arterial Hypertension

    Biotech: Biologics

    Multiple Sclerosis: Nervous System

    Diabetes: Type 2

    Nephrology: Kidney Function

    Diabetes: Type 2- Pediatric Issues

    Nephrology: Diseases of the Kidney

    Biology: Angiogenesis

    Lysosomal Storage Disorders: Fabry Disease

    Anxiety Disorders

    Cardiovascular: Clot formation and Vascular Injury

    Major Depressive Disorder

    Anticoagulation: Principles of Hemostasis and Bleeding Management

    Rheumatoid Arthritis: Biologic Therapy

    Osteoporosis: General

    Opioids: Pain Management

    Oncology Primer: Therapy Principles

    Dermatology: Immunology

    Anticoagulation: Standard Anticoagulants

    Multiple Sclerosis

    Rheumatoid Arthritis: Treatments with Nonbiologic DMARDS

    Anticoagulation: Treatments I

    Lupus: Treatments

    Rheumatoid Arthritis: Clinical Presentation and Assessment

    Drug R&D: Combination Product Regulatory Requirements

    Multiple Sclerosis: Oral Therapies

    Psoriasis: Biologics

    Obesity

    Diabetes: Type 1- Pathophysiology

    Psoriasis: Clinical Picture

    Alzheimer's Disease: Diagnostic Criteria

    Stroke: Annotated Studies

  • Microlearning Topics

  • Introduction

    Cardiovascular Disease (CVD)

    Atherosclerosis: Overview and Statistics

    Overview

    Atherosclerosis: Overview and Statistics

    Overview
    Statistics

    Prevalence and Incidence of CVD

    Statistics: Cardiovascular Disease (CVD)

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity, Diabetes and Cardiovascular Disease

    Atherosclerosis: Overview and Statistics

    Statistics

    Relationship between Obesity, Diabetes, and Cardiovascular Disease

    Obesity, Diabetes and Cardiovascular Disease

    Prevalence and Incidence of CVD

    Prevalence and Incidence of Cardiovascular Disease (CVD): Overview

    Atherosclerosis: Overview and Statistics

    Statistics

    Atherosclerosis: Treatments

    Intervention - Medications

    Atherosclerosis: Overview and Statistics

    Overview

    Atherosclerosis: Overview and Statistics

    Overview

    Pathophysiology

    Cardiovascular

    Atherosclerosis: Treatments

    Intervention - Medications

    GLP-1 Receptor Agonists and Cardiovascular Events

    GLP-1 Receptor Agonists: Effect of on Cardiovascular Events

    Atherosclerosis: Treatments

    Treatment of Atherosclerosis - Overview
    Intervention - Medications
    Intervention - Invasive...

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity, Diabetes and Cardiovascular Disease
    Obesity: Pathophysiology of Fat Cells
    Obesity...

    Introduction

    Overview
    Cardiovascular Disease (CVD)
    Routine Treatments
    New Therapies

    Residual Risk

    Common Complications: Cardiovascular

    Lymphatic System

    Lymphatic System
    Interactivity: Cardiovascular System Functions

    Relationship between Obesity, Diabetes, and Cardiovascular Disease

    Obesity and Insulin Resistance
    Obesity and Dyslipidemia
    Obesity and Hypertension
    Obes...

    Heart Failure: Overview and Statistics

    Heart Failure Introduction
    Overview
    Statistics

    Economic Burden of AF

    Total AF, Other Cardiovascular, and Noncardiovascular Costs

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity and Cardiovascular Mortality

    Heart Failure: Overview and Statistics

    Statistics

    Heart Failure: Overview and Statistics

    Overview

    Heart Failure: Overview and Statistics

    Statistics

    Heart Failure: Overview and Statistics

    Overview

    Atherosclerosis: Treatments

    Intervention - Medications

    Heart Failure: Treatments

    Emerging Therapies

    Atherosclerosis Contribution to Cardiovascular Diseases

    Atherosclerosis Contribution to Cardiovascular Diseases: Overview

    Complications

    Cardiovascular

    Heart Failure: Treatments

    Overview
    Prevention
    Treatment Guidelines
    Intervention - Medications
    ACE Inhibito...

    Atherosclerosis: Overview and Statistics

    Overview

    Atherosclerosis: Overview and Statistics

    Statistics

    Atherosclerosis: Overview and Statistics

    Statistics

    Atherosclerosis: Overview and Statistics

    Statistics

    Phase III Clinical Studies

    Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

    Clinical Trials: Cardiovascular Outcomes for Diabetes Drugs

    Common Outcomes in Diabetes Trials

    Additional Recommendations and Position Statements

    American Diabetes Association (ADA) Position Statement: Cardiovascular Disease and Risk Management

    Prevalence and Incidence of CVD

    Statistics

    2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

    Four Statin Benefit Groups

    Complications/Comorbidities of SLE

    Cardiovascular Disease (CVD)

    Atherosclerosis: Risk Factors

    Risk Factors

    Atherosclerosis: Risk Factors

    Risk Factors

    Atherosclerosis: Risk Factors

    Risk Factors

    Venous Thromboembolism (VTE) Clinical Picture

    Comorbid States: Cardiovascular Disease and Acute Myocardial Infarction (AMI)

    Prevalence and Incidence of CVD

    Statistics: Mortality

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity and Youth

    Cardiovascular Measures

    Electrocardiogram, Endpoints for Diabetes Studies: MACE

    Atherosclerosis Contribution to Cardiovascular Diseases

    Coronary Artery Disease

    Atherosclerosis Contribution to Cardiovascular Diseases

    Coronary Artery Disease: Myocardial Infarction

    Atherosclerosis Contribution to Cardiovascular Diseases

    Coronary Artery Disease: Heart Failure

    Atherosclerosis Contribution to Cardiovascular Diseases

    Coronary Artery Disease: Sudden Death

    Atherosclerosis Contribution to Cardiovascular Diseases

    Transient Ischemic Attack (TIA)

    Atherosclerosis Contribution to Cardiovascular Diseases

    Ischemic Stroke

    Atherosclerosis Contribution to Cardiovascular Diseases

    Peripheral Arterial Disease (PAD)

    Atherosclerosis Contribution to Cardiovascular Diseases

    Hypertension Secondary to Atherosclerosis

    Heart Failure: Risk Factors

    Risk Factors

    Heart Failure: Treatments

    Intervention - Medications
    ACE Inhibitors
    Angiotensin Receptor Blockers
    β-Blocke...

    Controversies in Androgen Replacement Therapy

    Cardiovascular

    Atherosclerosis: Causes

    Atherogenesis
    Fatty Streak
    Inflammation
    Leukocyte Recruitment
    Foam Cell Formatio...

    Role of the Heart and Circulatory System

    Location

    Role of the Heart and Circulatory System

    Cardiac Conduction

    Role of the Heart and Circulatory System

    Role of Circulation

    The Heart and Circulation: Anatomy

    Heart

    The Heart and Circulation: Anatomy

    Heart - Endocardium

    The Heart and Circulation: Anatomy

    Heart - Epicardium

    The Heart and Circulation: Anatomy

    Heart
    Heart - Endocardium
    Heart - Myocardium
    Heart - Epicardium

    Atherosclerosis: Diagnostic Tools/Biomarkers

    MRI

    Atherosclerosis: Causes

    Atherogenesis

    Atherosclerosis: Causes

    Fatty Streak

    Atherosclerosis: Causes

    Inflammation

    Atherosclerosis: Causes

    Leukocyte Recruitment

    Atherosclerosis: Causes

    Foam Cell Formation

    Atherosclerosis: Causes

    Atheroma Evolution

    Atherosclerosis: Causes

    Plaque Rupture

    Atherosclerosis: Causes

    Thrombus Formation

    Atherosclerosis: Complications

    Overview

    Atherosclerosis: Complications

    Coronary Artery Disease

    Atherosclerosis: Complications

    Ischemic Stroke

    Atherosclerosis: Complications

    Peripheral Arterial Disease (PAD)

    Atherosclerosis: Treatments

    Intervention - Medications

    Atherosclerosis: Treatments

    Intervention - Medications

    Atherosclerosis: Treatments

    Emerging Therapies

    Heart Failure: Overview and Statistics

    Overview

    Heart Failure: Overview and Statistics

    Statistics

    Heart Failure: Overview and Statistics

    Statistics

    Heart Failure: Risk Factors

    Risk Factors

    Heart Failure: Risk Factors

    Risk Factors

    Heart Failure: Diagnostic Tools/Biomarkers

    MRI

    Heart Failure: Diagnostic Tools/Biomarkers

    Biomarkers

    Heart Failure: Diagnostic Tools/Biomarkers

    Biomarkers

    Heart Failure: Diagnostic Tools/Biomarkers

    Biomarkers

    Heart Failure: Causes

    Index Event
    Nature of Index Event
    Compensatory Mechanisms
    Left Ventricular Remodeling

    Heart Failure: Causes

    Index Event

    Heart Failure: Causes

    Compensatory Mechanisms

    Heart Failure: Causes

    Compensatory Mechanisms

    Heart Failure: Causes

    Compensatory Mechanisms

    Heart Failure: Causes

    Compensatory Mechanisms

    Heart Failure: Complications

    Overview

    Heart Failure: Treatments

    Overview

    Heart Failure: Treatments

    Prevention

    Heart Failure: Treatments

    Treatment Guidelines

    Heart Failure: Treatments

    Intervention - Medications

    Heart Failure: Treatments

    ACE Inhibitors

    Heart Failure: Treatments

    β-Blockers

    Heart Failure: Treatments

    Diuretics

    Heart Failure: Treatments

    Aldosterone Antagonists

    Heart Failure: Treatments

    Vasodilators

    Heart Failure: Treatments

    Implantable Defibrillator

    Heart Failure: Treatments

    Heart Transplant

    Heart Failure: Treatments

    Prognosis

    Atherosclerosis: Complications

    Overview
    Coronary Artery Disease
    Transient Ischemic Attack (TIA)
    Ischemic Stroke

    Heart Failure: Diagnostic Tools/Biomarkers

    Physical Examination
    Routine Laboratory Testing
    Electrocardiogram (ECG)
    Chest X-Ray

    Atherosclerosis: Treatments

    Intervention - Invasive Techniques

    Heart Failure: Treatments

    Intervention - Invasive Techniques
    Implantable Defibrillator
    Cardiac Resynchronization The...

    Atherosclerosis: Treatments

    Treatment of Atherosclerosis - Overview

    Glycemic Control Intervention in Type 2 Diabetes: Heart2D

    Hyperglycemia and its Effect after Acute myocardial infaRction on cardiovascular outcomes in patient...

    Atherosclerosis: Diagnostic Tools/Biomarkers

    Laboratory Studies
    Coronary Angiography
    Intravascular Ultrasound
    Computed Tomography

    Heart Failure: Complications

    Overview
    Systolic Dysfunction (Reduced LV Ejection Fraction)
    Diastolic Dysfunction (Preser...

    Atherosclerosis Contribution to Cardiovascular Diseases

    Renal Artery Disease and Secondary Hypertension

    2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

    Statin Safety Recommendations

    2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

    Areas of Controversy

    Role of the Heart and Circulatory System

    Self Checks: Lungs, Heart. Vessels
    Location
    Appearance
    Heart is a Double Pump
    Ca...

    The Heart and Circulation: Anatomy

    AV Valves - Tricuspid Valve
    AV Valves - Mitral Valve

    The Heart and Circulation: Anatomy

    Semilunar Valves - Aortic Valve
    Semilunar Valves - Pulmonary Valve

    The Heart and Circulation: Physiology

    Conduction Sinus Node
    Conduction - AV Node

    Role of the Heart and Circulatory System

    Appearance

    Role of the Heart and Circulatory System

    Heart is a Double Pump

    Role of the Heart and Circulatory System

    Cardiac Cycle

    Role of the Heart and Circulatory System

    Cardiac Muscle

    Role of the Heart and Circulatory System

    Arteries, Veins, and Capillaries

    The Heart and Circulation: Anatomy

    Overview
    Chambers Right Atrium
    Chambers Right Ventricle
    Chambers Left Atrium
    ...

    The Heart and Circulation: Anatomy

    Overview

    The Heart and Circulation: Anatomy

    Chambers Right Ventricle

    The Heart and Circulation: Anatomy

    Chambers Left Ventricle

    The Heart and Circulation: Anatomy

    Chordae Tendineae

    The Heart and Circulation: Anatomy

    Papillary Muscles

    The Heart and Circulation: Anatomy

    Semilunar Valves - Aortic Valve

    The Heart and Circulation: Anatomy

    Semilunar Valves - Pulmonary Valve

    The Heart and Circulation: Anatomy

    Heart - Myocardium

    The Heart and Circulation: Physiology

    Cardiac Conduction - Overview

    The Heart and Circulation: Physiology

    Conduction Sinus Node

    The Heart and Circulation: Physiology

    Conduction - AV Node

    The Heart and Circulation: Physiology

    His-Purkinje System

    The Heart and Circulation: Physiology

    Cardiac Ion Channels

    The Heart and Circulation: Physiology

    Cardiac Output

    The Heart and Circulation: Physiology

    Stroke Volume

    The Heart and Circulation: Physiology

    Ejection Fraction

    Atherosclerosis: Diagnostic Tools/Biomarkers

    Coronary Angiography

    Atherosclerosis: Diagnostic Tools/Biomarkers

    Intravascular Ultrasound

    Atherosclerosis: Diagnostic Tools/Biomarkers

    Computed Tomography

    Atherosclerosis: Diagnostic Tools/Biomarkers

    Nuclear Medicine Techniques

    Atherosclerosis: Causes

    High-Risk Atherothrombotic Plaque

    Atherosclerosis: Causes

    Involvement of Platelets

    Atherosclerosis: Causes

    Platelet Activation

    Atherosclerosis: Complications

    Coronary Artery Disease

    Atherosclerosis: Complications

    Coronary Artery Disease

    Atherosclerosis: Complications

    Transient Ischemic Attack (TIA)

    Atherosclerosis: Treatments

    Intervention - Medications

    Atherosclerosis: Treatments

    Intervention - Medications

    Atherosclerosis: Treatments

    Intervention - Invasive Techniques

    Atherosclerosis: Treatments

    Intervention - Invasive Techniques

    Atherosclerosis: Treatments

    Intervention - Invasive Techniques

    Heart Failure: Diagnostic Tools/Biomarkers

    Physical Examination

    Heart Failure: Diagnostic Tools/Biomarkers

    Routine Laboratory Testing

    Heart Failure: Diagnostic Tools/Biomarkers

    Electrocardiogram (ECG)

    Heart Failure: Diagnostic Tools/Biomarkers

    Chest X-Ray

    Heart Failure: Causes

    Nature of Index Event

    Heart Failure: Causes

    Left Ventricular Remodeling

    Heart Failure: Causes

    Left Ventricular Remodeling

    Heart Failure: Causes

    Left Ventricular Remodeling

    Heart Failure: Complications

    Congestion/Fluid Retention

    Heart Failure: Complications

    Acute Heart Failure

    Heart Failure: Complications

    Stages of Heart Failure

    Heart Failure: Treatments

    Angiotensin Receptor Blockers

    Heart Failure: Treatments

    Digitalis Glycosides (Digoxin)

    Heart Failure: Treatments

    Intervention - Invasive Techniques

    Heart Failure: Treatments

    Cardiac Resynchronization Therapy

    Atherosclerosis: Complications

    Coronary Artery Disease

    The Heart and Circulation: Physiology

    Cardiac Conduction - Overview
    Conduction Sinus Node
    Conduction - AV Node
    His-Purkinj...

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Prevalence of Obesity in Adults Aged 20+ Years by WHO Region (2008)
    Obesity and Type 2 Diabetes...

    The Heart and Circulation: Anatomy

    Chambers Right Atrium

    The Heart and Circulation: Anatomy

    Chambers Left Atrium

    The Heart and Circulation: Anatomy

    Chambers Right Atrium
    Chambers Right Ventricle
    Chambers Left Atrium
    Chambers Left...

    The Heart and Circulation: Anatomy

    AV Valves - Tricuspid Valve

    The Heart and Circulation: Anatomy

    AV Valves - Mitral Valve

    The Heart and Circulation: Anatomy

    Coronary Arteries - Overview

    The Heart and Circulation: Anatomy

    Coronary Arteries - Intima

    The Heart and Circulation: Anatomy

    Coronary Arteries - Media

    The Heart and Circulation: Anatomy

    Coronary Arteries - Adventitia

    The Heart and Circulation: Physiology

    Pressure-Volume Loops/Relationships

    Atherosclerosis: Diagnostic Tools/Biomarkers

    Laboratory Studies

    Atherosclerosis: Treatments

    Intervention - Invasive Techniques

    Atherosclerosis: Treatments

    Intervention - Invasive Techniques

    Heart Failure: Diagnostic Tools/Biomarkers

    2-D Echocardiogram/Doppler

    Heart Failure: Complications

    Systolic Dysfunction (Reduced LV Ejection Fraction)

    Heart Failure: Complications

    Diastolic Dysfunction (Preserved LV Ejection Fraction)

    Heart Failure: Treatments

    Left Ventricular Assist Device (LVAD)

    Complications

    Oxygen Toxicity
    Pulmonary Barotrauma/Volutrauma
    Cardiovascular
    Other Complications

    2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

    Primary Prevention in Individuals ≥21 Years of Age With LDL-C ≥190 mg/dL Without ASCVD

    2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

    Primary Prevention in Individuals With Diabetes Without Clinical ASCVD

    2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

    Primary Prevention in Individuals Without Diabetes and With LDL-C 70-189 mg/dL

    The Heart and Circulation: Anatomy

    Coronary Arteries - Overview
    Coronary Arteries - Intima
    Coronary Arteries - Media
    Cor...

    The Heart and Circulation: Physiology

    Fractional Shortening

    The Heart and Circulation: Physiology

    Fractional Shortening

    The Heart and Circulation: Physiology

    Fractional Shortening

    Association of Obesity, Diabetes, and Cardiovascular Disease

    Obesity Trends Among U.S. Adults (BRFSS)

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity

    Cardiovascular Measures

    Heart Failure in T2DM

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity: Pathophysiology of Fat Cells

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity and Diabetes Risk

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity and the Metabolic Syndrome

    Relationship between Obesity, Diabetes, and Cardiovascular Disease

    Obesity and Insulin Resistance

    Relationship between Obesity, Diabetes, and Cardiovascular Disease

    Obesity and Dyslipidemia

    Relationship between Obesity, Diabetes, and Cardiovascular Disease

    Obesity and Hypertension

    Relationship between Obesity, Diabetes, and Cardiovascular Disease

    Worldwide Rates of Overweight and Obesity

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity and Type 2 Diabetes: Adults

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Obesity and Type 2 Diabetes: Youth

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Overweight and Obesity in Youth

    Phase III Clinical Studies

    Dulaglutide and Risk for Cardiovascular Events

    Relationship between Obesity, Diabetes and Cardiovascular Disease

    Prevalence of Obesity in Adults Aged 20+ Years by WHO Region (2008)

    Blood

    Plasma

    Introduction

    Routine Treatments

    Learning Objectives

    Learning Objectives

    Learning Objectives

    Learning Objectives

    Introduction

    Platelet Development Pathway

    Platelet Receptor Physiology

    Thromboxane A2

    Measures of Platelet Aggregation

    Light Transmission Aggregometry: Effects Shown

    Learning Objectives

    Learning Objectives

    Introduction and Learning Objectives

    Introduction and Learning Objectives

    Complications of Atrial Fibrillation (AF)

    Overview

    Blood Vessels

    Types of Blood Vessels

    Introduction and Learning Objectives

    Introduction and Learning Objectives

    Venous Thromboembolism (VTE) Clinical Picture

    Summary of Epidemiology

    Introduction

    Introduction

    Introduction and Learning Objectives

    Introduction and Learning Objectives

    Statins

    Efficacy and Safety: Secondary Prevention

    Introduction

    Overview

    ACC/AHA Treatment Guidelines for ACS: Statistics

    Prevalence and Incidence: CVD Statistics

    Atherothrombosis

    Platelets and Development of Atherosclerotic Lesions: Platelet Interaction with Endothelial Cells

    Introduction

    Introduction

    Introduction

    Introduction and Learning Objectives

    Diagnosis and Monitoring

    Overview

    Vascular Anatomy

    Introduction: Vascular Anatomy

    Anatomy of the Heart

    Overview: The Heart

    Ticlopidine

    Ticlopidine: Overview

    Blood Vessels

    Major Circulatory Systems

    Atrial Fibrillation (AF)

    Overview: Atrial Fibrillation

    Introduction: Interventional Cardiology

    Interventional Cardiology: Definition and Advantages

    Blood

    Composition

    Heart

    Regulation of CV Function

    Hemostasis

    Control of Hemostatic Pathways

    Platelet Receptor Physiology

    ADP

    Anticoagulant Reversal Agents

    Summary of Anticoagulation Reversal Agents

    Introduction

    Introduction and Learning Objectives

    Introduction to Heart Failure

    Introduction and Learning Objectives

    Treatment Guidelines: Introduction

    Treatment Guidelines: Introduction

    Blood

    Hematopoiesis

    Blood

    Blood Volume

    Venous Thromboembolism (VTE) Clinical Picture

    Incidence and Age

    Complications of Atrial Fibrillation (AF)

    Thromboembolic Complications

    Coronary Atherosclerosis: Overview

    Risk Factors on the Rise

    Drug Therapy in ACS: Overview

    Inhibitors of Renin-Angiotensin System

    Atherothrombosis

    Platelets and Arterial Thrombosis: Causes of Plaque Disruption

    Measures of Platelet Aggregation

    Overview: Platelets

    Bleeding in ACS: Clinical Definition of Bleeding

    Classification of Bleeding

    Drug Therapy in ACS: Overview

    STEMI: Analgesia

    Introduction: Interventional Cardiology

    Interventional Cardiology: Embolic Protection and Percutaneous Heart Valve Interventions

    Introduction: Interventional Cardiology

    Coronary Angiography: Left Coronary Angiogram

    Introduction: Interventional Cardiology

    Coronary Angiography: Left Coronary Angiogram in the Right Anterior Oblique

    Selected Basal Insulin Clinical Trials

    DEVOTE

    Blood

    Blood Volume

    Clinical Implications of Clot Formation

    Arterial and Venous Thrombosis

    Ezetimibe (Zetia)

    Efficacy and Safety: IMPROVE-IT Trial

    Niacin (Nicotinic Acid)

    Efficacy and Safety: Niacin Therapy

    BED Disease State

    Metabolic Syndrome Components: Dyslipidemia, Hypertension, and Type 2 Diabetes

    Phase III Clinical Studies

    Phase III Development Program

    Clopidogrel Clinical Trials

    CURE Study

    Management of Patients with Atrial Fibrillation

    Management Goals and Factors to Consider

    Pathophysiology of Atrial Fibrillation

    Atrial Fibrillation Maintaining Mechanisms

    VTE Clinical Picture: Epidemiology

    Summary of Epidemiology

    Heart

    Functions: Blood Collection

    Cardiac Cycle

    Integrated Review

    Hemostasis

    Fibrinolysis

    Atherothrombosis

    Involvement of Platelets

    Measures of Platelet Aggregation

    Light Transmission Aggregometry: Overview

    Pathophysiology of Atherothrombosis: Overview

    Atherogenesis: Overview

    ACC/AHA Treatment Guidelines for ACS: Statistics

    Diagnosis by Clinician: UA/NSTEMI

    Drug Therapy in ACS: Overview

    Drug Therapy in ACS: Overview

    Drug Therapy in ACS: Overview

    Drug Therapy in ACS: ACC/AHA Guidelines

    Drug Therapy in ACS: Overview

    Thienopyridines Approved for Antiplatelet Therapy

    Drug Therapy in ACS: Overview

    Approved GP IIb/IIIa Antagonists

    Bleeding in ACS: Clinical Definition of Bleeding

    Incidence of Bleeding

    Bleeding in ACS: Clinical Definition of Bleeding

    Transfusion Risks

    Introduction: Interventional Cardiology

    Coronary Angiography

    Introduction: Interventional Cardiology

    Coronary Angiography: Normal Left Coronary Angiogram

    Introduction: Interventional Cardiology

    Coronary Angiography: Right Coronary Angiogram

    Introduction: Interventional Cardiology

    Coronary Angiography: Left Ventricular Angiogram

    Introduction: Interventional Cardiology

    Coronary Artery Bypass Graft (CABG) Surgery

    Percutaneous Coronary Intervention (PCI)

    Mechanism of Revascularization

    Percutaneous Coronary Intervention (PCI)

    The Point of Access for PCI

    Intracoronary Stents

    Overview: Stent Implantation

    Intracoronary Stents

    Bare Metal Stents (BMS)

    Intracoronary Stents

    Drug-Eluting Stents (DES): Restenosis

    Stent Thrombosis

    Drug-Eluting Stents (DES)

    Stent Thrombosis

    Duration of Dual Antiplatelet Therapy: Clopidogrel

    Role of the Heart and Circulatory System

    Overview: Heart and Circulatory System

    Anatomy of the Heart

    Heart: Three Layers

    Anatomy of the Heart

    Heart: Endocardium

    Anatomy of the Heart

    Heart: Epicardium

    Cardiac Cycle

    Pressure-Volume Loops/Relationships: Variables in Ventricular Function

    Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

    DVT and PE Diagnosis Guidelines

    Pathophysiology of Atrial Fibrillation

    Atrial Fibrosis

    Clopidogrel Clinical Trials

    PCI-CURE Study

    Thienopyridines

    Prasugrel

    Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

    VTE Diagnosis: Clinical Methods

    Disease State

    Etiology of Hyperlipidemia - Secondary

    Insulin Glargine: Lantus

    The Outcome Reduction with Initial Glargine Intervention trial (ORIGIN)

    Phase 3 Clinical Studies

    Dulaglutide: REWIND

    Drug Therapy in ACS: Overview

    UA/NSTEMI: Analgesic Therapy: Morphine

    Causes of Atrial Fibrillation (AF), Associated Conditions

    Associated Heart Disease

    Causes of Atrial Fibrillation

    Reversible Conditions and Associated Heart Disease

    Treatment Goals and Modalities

    2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults

    Special Populations

    NLA: Hispanics/Latinos

    Definition of Venous Thromboembolism (VTE)

    Impaired Gas Exchange During Pulmonary Embolism (PE) and Upper Extremity DVT

    Clopidogrel Clinical Trials

    PCI-CLARITY Study

    Major Adverse Cardiac Events (MACE)

    Major Adverse Cardiac Events (MACE)

    Causes of Atrial Fibrillation

    Causes of Atrial Fibrillation: Overview

    VTE Prevention Guidelines

    Prevention in Surgical Patients: Orthopedic Surgery

    Complications of Atrial Fibrillation (AF)

    Thromboembolic Complications: Transient Ischemic Attacks and Stroke

    Diabetes Clinical Trials Studying Complications

    DCCT/EDIC Study

    Blood Vessels

    Structure and Function

    Blood Vessels

    Structure and Function: Tunica Adventitia

    Heart

    Cardiac Myocytes: Sarcomeres and Myofibrils

    Heart

    Cardiac Myocytes: Myofilaments

    Heart

    Cardiac Conduction System: Overview

    Heart

    Cardiac Conduction System: Cardiac Rate Control

    Heart

    Location

    Heart

    Pericardium

    Heart

    Cardiac Myocytes: Characteristics

    Cardiac Cycle

    Electrocardiogram (ECG): P Wave, PR Interval, QRS Complex

    Introduction

    Platelets

    Hemostasis

    Overview: Hemostasis

    Hemostasis

    Clot Retraction and Vessel Repair

    Hemostasis

    Disorders of Hemostasis: Abnormal Bleeding

    Hemostasis

    Platelet Aggregation

    Hemostasis

    Hemostasis

    Atherothrombosis

    Overview: Atherothrombosis

    Atherothrombosis

    Overview: Atherosclerotic Process

    Atherothrombosis

    Platelets and Development of Atherosclerotic Lesions

    Platelet Receptor Physiology

    ADP and Thromboxane A2

    Platelet Receptor Physiology

    IIb/IIIa and Platelet Aggregation

    Platelet Receptor Physiology

    IIb/IIIa as a Target

    Measures of Platelet Aggregation

    VerifyNow: Overview

    Measures of Platelet Aggregation

    Measure of Platelet Biomarkers VASP: PGE-1

    Measures of Platelet Aggregation

    Light Transmission Aggregometry: MPA & IPA

    Measures of Platelet Aggregation

    Point-of-Care Devices

    Clopidogrel

    Genetic Variation

    Stent Thrombosis

    Clopridogrel Resistance and Poor Response

    Coronary Atherosclerosis: Overview

    Genetic Predisposition

    Pathophysiology of Atherothrombosis: Overview

    Atherogenesis: Lesion

    Pathophysiology of Atherothrombosis: Overview

    Plaque Rupture

    Acute Coronary Syndrome (ACS): Overview

    Pathogenesis of ACS

    ACC/AHA Treatment Guidelines for ACS: Statistics

    Diagnosis by Clinician: Treatment of UA/NSTEMI

    Drug Therapy in ACS: Overview

    Thienopyridines: Adenosine Diphosphate (ADP) Receptor (P2Y12) Antagonists

    Drug Therapy in ACS: Overview

    GP IIb/IIIa Antagonists

    Drug Therapy in ACS: Overview

    Unfractionated Heparin (UFH)

    Drug Therapy in ACS: Overview

    STEMI: Reperfusion

    Bleeding in ACS: Clinical Definition of Bleeding

    Clinical Consequences of Bleeding

    Introduction: Interventional Cardiology

    Cardiac Catheterization: Historical Perspective

    Introduction: Interventional Cardiology

    Coronary Balloon Angioplasty

    Percutaneous Coronary Intervention (PCI)

    Percutaneous Coronary Intervention (PCI): Indications

    Intracoronary Stents

    Intracoronary Stents: Overview

    Intracoronary Stents

    Balloon Angioplasty and Intracoronary Stent Placement: Balloon Inflation in LAD

    Intracoronary Stents

    Balloon Angioplasty and Intracoronary Stent Placement: LAD After Stent Insertion and Balloon Dilatat...

    Intracoronary Stents

    Drug-Eluting Stents (DES): Thienopyridine and Aspirin

    Intracoronary Stents

    Adjunctive Drug Therapy: Heparin

    Stent Thrombosis

    Stent Thrombosis: Use in Patients with PCI

    Stent Thrombosis

    Timing and Incidence: Acute/Subacute Stent Thrombosis

    Stent Thrombosis

    Bare Metal Stents (BMS)

    Stent Thrombosis

    Risk Factors: Early and Late Stent Thrombosis

    Stent Thrombosis

    Very Late Stent Thrombosis

    Stent Thrombosis

    Duration of Dual Antiplatelet Therapy: Premature Cessation

    Stent Thrombosis

    Duration of Dual Antiplatelet Therapy: Incidence and Predictors

    Anatomy of the Heart

    Introduction: The Heart

    Anatomy of the Heart

    Heart: Myocardium

    Cardiac Cycle

    Stroke Volume

    Cardiac Conduction

    Introduction: Cardiac Conduction

    Clot Formation

    Secondary Hemostasis: Coagulation Cascade

    Causes of Atrial Fibrillation (AF), Associated Conditions

    Causes of Atrial Fibrillation (AF): Overview

    Pathophysiology of Atrial Fibrillation (AF)

    Mechanisms of Atrial Fibrillation (AF): Abnormal Electrical and Ectopic Impulse Conduction

    Venous Thromboembolism (VTE) Clinical Picture

    Incidence: Other Factors

    Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

    VTE Treatment Guidelines: Overview

    Introduction

    New Therapies

    VTE Clinical Picture: Risk Factors and Comorbid States

    Comorbid States

    Diagnosis and Monitoring

    Risk Assessment and Screening

    Definition of Venous Thromboembolism (VTE)

    Venous Thromboembolism (VTE) Location and the Relationship between DVT and PE

    Anatomy of the Heart

    Introduction: The Heart
    Overview: The Heart
    Chambers: Right and Left Atrium, Right and Lef...

    Selected Basal Insulin Clinical Trials

    Glargine vs. Standard of Care

    Special Populations

    NLA: Children and Adolescents

    Statins

    Efficacy and Safety: Primary Prevention

    Macrovascular Complications

    Blood Pressure, Dyslipidemia

    Insulin Glargine: Lantus

    Safety

    BED Disease State

    Metabolic Syndrome and Metabolic Risk Factors

    Coronary Atherosclerosis: Overview

    Risk Factors and Atherosclerosis

    Male Reproductive Physiology

    Testosterone

    Clopidogrel Clinical Trials

    CHARISMA Study

    Pathophysiology of Atrial Fibrillation (AF)

    Atrial Fibrosis

    Clinical Prevention

    Primary Prevention

    Treatment and Prevention of Cancer-associated VTE

    Surgery Patients

    Epidemiology and Natural History

    Prevalence of Organ System Involvement in the HOS

    Blood

    Composition
    Functions: Transportation, Regulation, Protection
    Functions: Red Blood Cells, ...

    Typical Clinical Course

    Organ Systems Involved

    Introduction: Atrial Fibrillation

    Introduction: Atrial Fibrillation

    Thromboembolic Complications

    Risk Stratification: CHADS2 Limitations

    Management of Patients with Atrial Fibrillation

    Rate Control: Pharmacological Therapy

    Management of Patients with Atrial Fibrillation

    Preventing Thromboembolism: Anticoagulation

    Introduction

    Introduction: Venous Thromboembolism

    VTE Prevention Guidelines

    Venous Thromboembolism (VTE) Prophylaxis

    VTE Prevention Guidelines

    ACCP, AAOS, ASRA Compendium of Consensus Recommendations for VTE Prophylaxis

    VTE Prevention Guidelines

    Prevention in Surgical Patients: Non-Orthopedic Surgery

    VTE Prevention Guidelines

    Special Situations and Procedures for High Risk of Bleeding

    Blood

    Functions: Transportation, Regulation, Protection

    Blood

    Functions: Red Blood Cells, White Blood Cells, and Platelets

    Blood Vessels

    Structure and Function: Tunica Media

    Lymphatic System

    Lymphatic System

    Heart

    Cardiac Myocytes: Intercalated Discs

    Heart

    Cardiac Myocytes: Action Potentials

    Heart

    Left and Right Sides

    Heart

    Coronary Vasculature

    Cardiac Cycle

    Overview

    Cardiac Cycle

    Pressure and Volume: Rapid Ejection

    Cardiac Cycle

    Pressure and Volume: Reduced Ejection

    Cardiac Cycle

    Pressure and Volume: Ventricle Relaxation

    Cardiac Cycle

    Phases

    Cardiac Cycle

    Electrocardiogram (ECG): Overview

    Cardiac Cycle

    Electrocardiogram (ECG): Diagnosis

    Cardiac Cycle

    Pressure and Volume: Atrial Contraction

    Cardiac Cycle

    Pressure and Volume: Isovolumetric Contraction

    Introduction

    Normal Values

    Hemostasis

    Disorders of Hemostasis: Thromboembolic Conditions

    Hemostasis

    Vascular Spasms

    Hemostasis

    Platelet Plug Formation

    Hemostasis

    Activated Platelets

    Atherothrombosis

    Superficial Plaque Erosion

    Atherothrombosis

    Platelets and Arterial Thrombosis

    Platelet Receptor Physiology

    Substances That Cause Platelet Aggregation

    Platelet Receptor Physiology

    Activation Pathways

    Platelet Receptor Physiology

    Thrombin

    Measures of Platelet Aggregation

    VerifyNow: P2Y12 Cartridge

    Measures of Platelet Aggregation

    Summary: Platelets

    Measures of Platelet Aggregation

    Light Transmission Aggregometry: Aggregometer

    Measures of Platelet Aggregation

    Light Transmission Aggregometry: Residual Aggregation

    Measures of Platelet Aggregation

    Other Methods of Assessing Platelet Aggregation

    Introduction

    Introduction: Thienopyridines

    Clopidogrel Clinical Trials

    High Loading Dose Studies

    Clopidogrel Clinical Trials

    CAPRIE

    Introduction

    Introduction: Acute Coronary Syndrome

    Pathophysiology of Atherothrombosis: Overview

    Pathophysiology of Atherothrombosis: Overview

    Pathophysiology of Atherothrombosis: Overview

    Atherogenesis

    Pathophysiology of Atherothrombosis: Overview

    Thrombus Formation

    Acute Coronary Syndrome (ACS): Overview

    Acute Coronary Syndrome (ACS): Overview

    Acute Coronary Syndrome (ACS): Overview

    Presentations of UA/NSTEMI

    Acute Coronary Syndrome (ACS): Overview

    STEMI

    ACC/AHA Treatment Guidelines for ACS: Statistics

    Recognition of Symptoms by Patient

    ACC/AHA Treatment Guidelines for ACS: Statistics

    Diagnosis by Clinician: Management of Patients

    Drug Therapy in ACS: Overview

    UA/NSTEMI: Anti-Ischemic Therapy

    Drug Therapy in ACS: Overview

    Nitrates

    Drug Therapy in ACS: Overview

    Beta Adrenergic Blockers

    Drug Therapy in ACS: Overview

    Calcium Channel Blockers

    Drug Therapy in ACS: Overview

    UA/NSTEMI: Antiplatelet Therapy

    Drug Therapy in ACS: Overview

    UA/NSTEMI: Anticoagulants

    Drug Therapy in ACS: Overview

    Low-Molecular-Weight Heparins (LMWHs)

    Drug Therapy in ACS: Overview

    Direct Thrombin Inhibitors

    Drug Therapy in ACS: Overview

    Factor Xa Inhibitors

    Drug Therapy in ACS: Overview

    Long-Term Anticoagulation (Warfarin/Coumarin)

    Drug Therapy in ACS: Overview

    STEMI: Anti-Ischemic Therapy Beta Blockers

    Bleeding in ACS: Clinical Definition of Bleeding

    Challenges

    Bleeding in ACS: Clinical Definition of Bleeding

    Need for Standardization of Bleeding Definition

    Bleeding in ACS: Clinical Definition of Bleeding

    Bleeding Risk

    Bleeding in ACS: Clinical Definition of Bleeding

    Minimizing Bleeding

    Introduction: Interventional Cardiology

    Cardiac Catheterization

    Introduction: Interventional Cardiology

    Stents

    Introduction: Interventional Cardiology

    Coronary Artery Bypass Graft (CABG) Surgery

    Percutaneous Coronary Intervention (PCI)

    PCI Aftercare

    Intracoronary Stents

    Balloon Angioplasty and Intracoronary Stent Placement: Left Anterior Descending Coronary Artery

    Intracoronary Stents

    Balloon Angioplasty and Intracoronary Stent Placement: Angiography After Balloon Dilatation of LAD

    Intracoronary Stents

    Adjunctive Drug Therapy

    Stent Thrombosis

    Definitions: Protocol Definitions and Limitations

    Stent Thrombosis

    Definitions: Protocol Definitions and Potential Bias

    Stent Thrombosis

    Mechanisms for Stent Thrombosis

    Stent Thrombosis

    Late Stent Thrombosis

    Stent Thrombosis

    Duration of Dual Antiplatelet Therapy: BASKET-LATE Trial

    Stent Thrombosis

    Long-Term Comparison of BMS and DES: Late Stent Thrombosis

    Prasugrel Clinical Trials

    Recurrent Events Data: Results and Conclusion

    Vascular Anatomy

    Interactivity: Vascular Anatomy

    Role of the Heart and Circulatory System

    Appearance: Pericardium

    Role of the Heart and Circulatory System

    The Heart is a Double Pump

    Role of the Heart and Circulatory System

    Role of Circulation

    Anatomy of the Heart

    Summary: Chambers of the Heart

    Anatomy of the Heart

    Overview: Anatomy of the Heart

    Anatomy of the Heart

    Summary: Coronary Arteries

    Cardiac Cycle

    Cardiac Cycle

    Cardiac Cycle

    Cardiac Muscle

    Cardiac Cycle

    Cardiac Output

    Cardiac Cycle

    Ejection Fraction

    Cardiac Conduction

    Cardiac Conduction System

    Cardiac Conduction

    Conduction: Sinus Node

    Cardiac Conduction

    Conduction: AV Node

    Cardiac Conduction

    His-Purkinje System

    Blood

    Plasma

    Blood

    Blood Composition

    Patient Types and Risk Factors for Bleeding

    Hemostasis and Bleeding Disorders

    Patient Types and Risk Factors for Bleeding

    Bleeding Disorders and Hypercoagulable States

    Atrial Fibrillation (AF)

    Atrial Fibrillation (AF) Definition

    Causes of Atrial Fibrillation (AF), Associated Conditions

    Atrial Fibrillation Without Associated Heart Disease

    Pathophysiology of Atrial Fibrillation (AF)

    Myocardial and Hemodynamic Consequences

    Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

    DVT and PE Diagnosis Guidelines: Institute for Clinical Systems Improvement (ICSI)

    Venous Thromboembolism (VTE) Prevention Guidelines

    Venous Thromboembolism (VTE) Primary Prophylaxis

    Complications of Atrial Fibrillation (AF)

    Risk Stratification: CHADS2

    CABG- Introduction and Overview

    CABG- Introduction and Overview

    Anatomy and Physiology

    Mechanism of MI from CAD

    Goals of Male Hypogonadism Replacement Therapy

    Goals of Treatment for Male Hypogonadism

    Blood Vessels

    Major Circulatory Systems
    Types of Blood Vessels
    Structure and Function
    Structure and...

    Management of Patients with Atrial Fibrillation

    Overview of Strategies and Rate Control

    Aspirin and Primary Stroke Prevention

    Aspirin and Primary Stroke Prevention: Recommendations

    Pathophysiology of Atrial Fibrillation

    Triggers and Mechanisms of Atrial Fibrillation

    Epidemiology and Risk Factors

    Proatherogenic Risk Factors

    Overview of DVT and PE Diagnosis and Treatment

    VTE Diagnosis: Clinical Methods

    Overview of DVT and PE Diagnosis and Treatment

    DVT and PE Diagnosis and Treatment Guidelines

    VTE Prevention Guidelines

    VTE Prevention in Medical Patients

    Economic Burden of AF

    Kim and Associates Study: The Annual Projected National Incremental Cost of AF

    Cholesterol Metabolism, Lipoproteins, and Residual Risk: Introduction

    Cholesterol Metabolism, Lipoproteins, and Residual Risk: Introduction

    PCSK9 Inhibitors

    Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

    Management of Patients with Atrial Fibrillation

    Rhythm Control: Nonpharmacological Methods

    Epidemiology and Natural History

    Clinical Manifestations: Physical

    Clopidogrel Clinical Trials

    PCI Studies

    Blood Vessels

    Structure and Function: Tunica Intima

    Cardiac Cycle

    Pressure and Volume: Reduced Ventricular Filling

    Cardiac Cycle

    Electrocardiogram (ECG): Measurements

    Atherothrombosis

    High-Risk Atherothrombotic Plaque

    Measures of Platelet Aggregation

    VerifyNow: PRU: P2Y12 Reaction Units

    Measures of Platelet Aggregation

    Measure of Platelet Biomarkers VASP

    Measures of Platelet Aggregation

    Light Transmission Aggregometry: Tracing

    Clopidogrel Clinical Trials

    Registration Studies

    Role of the Heart and Circulatory System

    Summary: Functions of the Heart

    Coronary Atherosclerosis: Overview

    Inflammation and Atherosclerosis: ACS

    Coronary Atherosclerosis: Overview

    Inflammation and Atherosclerosis: Atherogenesis

    Coronary Atherosclerosis: Overview

    Inflammation and Atherosclerosis Inflammation, Plaque Rupture, and Thrombosis

    Acute Coronary Syndrome (ACS): Overview

    UA/NSTEMI

    Drug Therapy in ACS: Overview

    Facilitated PCI

    Introduction: Interventional Cardiology

    Cardiac Catheterization: Indications

    Percutaneous Coronary Intervention (PCI)

    Percutaneous Coronary Intervention (PCI): Overview

    Percutaneous Coronary Intervention (PCI)

    Percutaneous Coronary Intervention (PCI): Overview

    Stent Thrombosis

    Very Late and Cumulative Effects

    Clopidogrel Clinical Trials

    CHARISMA: Asymptomatic and Symptomatic

    Anatomy of the Heart

    Chambers: Right and Left Atrium, Right and Left Ventricles

    Anatomy of the Heart

    Coronary Veins

    Cardiac Cycle

    Fractional Shortening

    Cardiac Cycle

    Summary: Cardiac Cycle

    Blood

    Functions of Blood

    Clot Formation

    Coagulation and Hemostasis Overview

    Overview of Bleeding Risk Schemes

    ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation)

    Considerations in the Treatment of Bleeding

    HASHTI and American Society of Hematology Definitions

    Atrial Fibrillation (AF)

    Normal Atrial Contraction and Electrocardiogram (ECG)

    Atrial Fibrillation (AF)

    Classification of Atrial Fibrillation (AF)

    Causes of Atrial Fibrillation (AF), Associated Conditions

    Familial Atrial Fibrillation
    Obesity and Atrial Fibrillation

    Pathophysiology of Atrial Fibrillation (AF)

    Atrial Fibrillation (AF) Maintaining Mechanisms

    Definition of Venous Thromboembolism (VTE)

    Venous Thromboembolism (VTE) Overview

    Definition of Venous Thromboembolism (VTE)

    Hemodynamic Response to Pulmonary Embolism (PE)

    Complications of Atrial Fibrillation (AF)

    Virchow's Triad

    Indications

    Indications for CABG

    Choice of Vessel Graft

    Additional Factors Affecting the Choice of Vessel Graft

    Total vs. Incomplete Revascularization

    Total Revascularization

    Anatomy and Physiology

    Normal Coronary Circulation

    Clinical Presentation and Diagnosis

    Presentation

    Clinical Presentation and Diagnosis

    Knowledge Check: Clinical Presentation and Diagnosis

    Clinical Management and Treatment

    Management and Treatment

    Male Reproductive Physiology

    Testes
    Testosterone

    Dyslipidemia Disease State

    Etiology

    Insulin Resistance in Type 2 Diabetes Mellitus

    Obesity and Dyslipidemia-associated Insulin Resistance

    VTE Clinical Picture: Risk Factors and Comorbid States

    Risk Factors and Comorbid States

    Epidemiology

    Risk Factors - Obesity

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    ROCKET Atrial Fibrillation

    Thromboembolic Complications

    Risk of Thromboembolism

    Management of Patients with Atrial Fibrillation

    Rhythm Control and Preventing Thromboembolism

    VTE Prevention Guidelines

    (VTE) Prophylaxis: Patient-Related Thromboembolism Risk Factors

    Rivaroxaban Clinical Trials: Acute Coronary Syndrome

    ATLAS-ACS2 Trial

    Economic Burden of AF

    Kim and Associates Study: National Incremental Costs Incurred by Patients with AF

    Comorbidities and Health-Related Quality of Life in Patients with AF

    Comorbidities Commonly Associated with AF: Vascular Disease and CV Risk Factors

    PCSK9 Inhibitors

    Efficacy and Safety: Evolocumab

    Fibrates

    Side Effects, Efficacy, and Safety: Fibrates

    Cardiac Cycle

    Pressure and Volume: Isovolumetric Relaxation

    Cardiac Cycle

    Heart Sounds

    Hemostasis

    Coagulation: Phases

    Hemostasis

    Coagulation: Contact Activation Pathway

    Introduction

    Platelet Development Pathway
    Platelets
    Normal Values

    Bleeding in ACS: Clinical Definition of Bleeding

    Independent Predictors of Mortality

    Introduction: Interventional Cardiology

    Interventional Cardiology: Procedures

    Intracoronary Stents

    Drug-Eluting Stents (DES): Candidates for Drug-Eluting Stents

    Stent Thrombosis

    Stent Thrombosis: Overview

    Clopidogrel Clinical Trials

    MATCH Study

    Role of the Heart and Circulatory System

    Arteries, Veins, Capillaries

    Anatomy of the Heart

    Heart: Three Layers
    Heart: Endocardium
    Heart: Myocardium
    Heart: Epicardium

    Cardiac Conduction

    Summary: Cardiac Conduction

    Vascular Anatomy

    Tunica Intima, Tunica Media, and Tunica Adventitia

    Vascular Anatomy

    Summary: Vascular Anatomy

    Blood

    Summary: Blood

    Clot Formation

    Platelet Adhesion, Activation, and Aggregation

    Clinical Implications of Clot Formation

    Thrombosis and Virchow's Triad

    Overview of Bleeding Risk Schemes

    Bleeding Risk Stratification Schemes: HEMORR2HAGES

    Monitoring Patients at Risk of Thrombosis or Bleeding

    Laboratory Tests and Complete Blood Count (CBC)

    Considerations in the Treatment of Bleeding

    Basic Management of Bleeding: Minor and Major Bleeding

    Anticoagulant Reversal Agents

    Factor VIII Inhibitor Bypass Activity (FEIBA)

    Atrial Fibrillation (AF)

    Related Arrythmias

    AF Epidemiology

    Epidemiology of Atrial Fibrillation (AF): Overview

    AF Epidemiology

    Prevalence of AF

    Causes of Atrial Fibrillation (AF), Associated Conditions

    Reversible Conditions

    Venous Thromboembolism (VTE) Clinical Picture

    Recurrent VTE and Mortality After Initial VTE

    Venous Thromboembolism (VTE) Clinical Picture

    Risk Factors for VTE and Classification

    Venous Thromboembolism (VTE) Prevention Guidelines

    Venous Thromboembolism (VTE) Primary Prophylaxis: Surgical and Non-Surgical Patients

    Choice of Vessel Graft

    Choice of Vessel Graft

    Total vs. Incomplete Revascularization

    CABG Techniques

    Myocardial Infarction: Introduction and Overview

    Myocardial Infarction: Introduction and Overview

    Clinical Management and Treatment

    NSTEMI and Special Groups

    Clinical Management and Treatment

    Stress-induced Cardiomyopathy (Takotsubo)

    Prognosis

    Short-term Prognosis Post-MI (STEMI and NSTEMI)

    Clinical Prevention

    Secondary Prevention

    Statins

    Efficacy and Safety: Secondary Prevention

    Disease State

    Common Complications

    Impact of Diabetes

    Proportion of Global Non-Communicable Disease Deaths Under the Age of 70 (2008)

    Definition and Classification

    Disease State, Spectrum of Disorders

    Thromboembolic Complications

    Risk of Thromboembolism: Risk Stratification

    Thromboembolic Complications

    Thromboembolic Complications: Atrial Stunning During Cardioversion

    Overview: Venous Thromboembolism

    Relationship between DVT and PE

    Overview: Venous Thromboembolism

    Impaired Gas Exchange During Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT)

    VTE Clinical Picture: Risk Factors and Comorbid States

    VTE Risk Factor Classification

    VTE Clinical Picture: Natural History, Clinical Syndromes, Complications

    Complications Associated with VTE

    Overview of DVT and PE Diagnosis and Treatment

    VTE Diagnosis

    VTE Prevention Guidelines

    Prevention in Surgical Patients

    Apixaban Clinical Trials: Acute Coronary Syndrome

    APPRAISE2 Trial

    VTE Comorbidities and Health-Related Quality of Life

    Risk Categories for VTE

    Heart

    Internal Anatomy

    Stent Thrombosis

    ARC Definitions

    Anatomy of the Heart

    Left and Right Coronary Arteries

    Principles of Hemostasis

    Coagulation Cascade: Intrinsic and Extrinsic Pathways, Thrombin Generation and Thrombin Functions

    Monitoring Patients at Risk of Thrombosis or Bleeding

    Overview, Signs and Symptoms of Bleeding

    Monitoring Patients at Risk of Thrombosis or Bleeding

    Other Laboratory Tests

    Monitoring Patients at Risk of Thrombosis or Bleeding

    Other Laboratory Tests: Activated Partial Thromboplastin Time and Thrombin Time

    Monitoring Patients at Risk of Thrombosis or Bleeding

    Other Laboratory Tests: Ecarin Clotting Time and Heptest

    Anticoagulant Reversal Agents

    Overview: Anticoagulant Reversal Agents and Vitamin K

    Venous Thromboembolism (VTE) Clinical Picture

    Complications Associated with VTE

    Complications of Atrial Fibrillation (AF)

    Risk of Thromboembolism

    Complications of Atrial Fibrillation (AF)

    Thromboembolic Complications: Impact of Stroke in Atrial Fibrillation

    Choice of Vessel Graft

    Venous Grafts

    Choice of Vessel Graft

    Techniques for Harvesting Arterial Grafts

    Epidemiology

    Epidemiology of Myocardial Infarction

    Epidemiology

    Risk Factors

    Etiology

    Etiology

    Clinical Presentation and Diagnosis

    Diagnosis, Misdiagnosis

    Clinical Management and Treatment

    STEMI

    HAART-Associated Adverse Clinical Events

    Elevated Lipids

    Phase 3 Clinical Studies

    Phase 3 Development Program

    Epidemiology

    Risk Factors - Other Factors

    Treatment

    Lifestyle Modification: Exercise and Physical Activity

    Introduction to Monoclonal Antibodies

    Antibodies as Therapy
    Early Antibody Therapy: Polyclonal Antibodies
    Hybridoma Technology: ...

    Apixaban Clinical Trials: Venous Thromboembolism

    AMPLIFY Study

    Use of Novel Oral Anticoagulants

    Venous Thromboembolism (VTE)

    Epidemiology of Atrial Fibrillation

    Epidemiology of Atrial Fibrillation: Overview

    Causes of Atrial Fibrillation

    Atrial Fibrillation Without Associated Heart Disease - Lone AF

    Thromboembolic Complications

    Transient Ischemic Attacks and Stroke and Impact of Stroke in Atrial Fibrillation

    Overview: Venous Thromboembolism

    VTE Epidemiology and Venous Thromboembolism (VTE) Location

    VTE Prevention Guidelines

    Risk Assessment, Effect of Anticoagulant Prophylaxis, and Thromboprophylaxis Recommendations

    VTE Prevention Guidelines

    Prevention in Surgical Patients or Orthopedic Surgery

    Residual Risk

    Definition of Residual Vascular Risk

    Statins

    Discovery of Statins

    Emerging Therapies

    Cholesteryl Ester Transfer Protein Inhibitors

    Platelet Receptor Physiology

    Substances That Cause Platelet Aggregation
    Activation Pathways
    ADP and Thromboxane A2

    Vascular Anatomy

    Major Arteries and Veins

    Overview of Bleeding Risk Schemes

    Bleeding Risk Schemes

    Anticoagulant Reversal Agents

    Protamine Sulfate, Platelets and Fresh Frozen Plasma (FFP)

    Anticoagulant Reversal Agents

    Prothrombin Complex Concentrates (PCC) and the Recombinant Factor VIIa (rFVIIa)

    Atrial Fibrillation (AF)

    Clinical Manifestations of AF

    Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

    VTE Diagnosis Overview

    Complications of Atrial Fibrillation (AF)

    Risk Stratification: CHADS2 Limitations

    Use of Novel Oral Anticoagulants

    Novel Oral Anticoagulants

    Use of Novel Oral Anticoagulants

    Venous Thromboembolism (VTE)

    Technique: On-pump vs. Off-pump

    Different Bypass Procedures

    Clinical Presentation and Diagnosis

    Diagnosis

    Clinical Management and Treatment

    STEMI: Reperfusion and Complications

    Clinical Management and Treatment

    NSTEMI

    Biomarkers for the Diagnosis of AD

    Plasma Biomarkers

    Target Organ Damage

    Target Organ Damage

    Pharmacological Treatments

    Selective Serotonin Reuptake Inhibitors (SSRIs)

    Signs and Symptoms

    Damage to Specific CNS Regions

    Patient History

    Presenting Symptoms in MS Patients

    Epidemiology of Diabetes

    Impact of Diabetes

    Development of Monoclonal Antibodies

    Safety Risks of Immune System Targeting

    Psoriasis Therapies

    Retinoids: Adverse Effects

    What is the Role of Toxicology in Drug Development?

    Safety Pharmacology

    Potentially Modifiable Risk Factors

    Metabolic Syndrome, Oxidative Stress and Inflammation

    Potentially Modifiable Risk Factors

    Hyperlipidemia and Diet

    Mendelian Genetics

    History of Cholesterol and Atherosclerosis

    Glycemic Control Intervention in Type 2 Diabetes: ORIGIN

    The Outcome Reduction with Initial Glargine INtervention trial (ORIGIN)

    Phase III Data: ENGAGE AF-TIMI 48

    ENGAGE AF-TIMI 48: Conclusions

    Epidemiology

    Incidence and Prevalence: International Diabetes Federation

    Pathophysiology

    Pathophysiology

    Pathophysiology

    Common Complications

    VTE Clinical Picture: Risk Factors and Comorbid States

    Risk Factors and Comorbid States

    Management of Patients with Atrial Fibrillation

    Rate and Rhythm Control

    VTE Clinical Picture: Epidemiology

    Incidence, Prevalence, Recurrent VE and Mortality After Initial VTE

    Risk Factors for Atherosclerosis

    Risk Factors and Atherosclerosis

    AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

    Treatment Recommendations

    Heart

    Functions: Blood Collection
    Cardiac Myocytes: Sarcomeres and Myofibrils
    Cardiac Myocytes: ...

    Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Diagnosis and Treatment Guidelines

    VTE Diagnosis: Signs and Symptoms of PE

    Treatment

    Lifestyle Modification: Nutrition

    Aspirin and Primary Stroke Prevention

    Recommendations: Low Dose Aspirin

    Comorbid Conditions

    Comorbid Chronic Medical Conditions

    Summary: Pathology of Diabetes Complications

    Summary: Pathology of Diabetes Complications

    Hypersensitivity

    Type I Hypersensitivity Reaction: Immediate Hypersensitivity

    Lifestyle Modifications and Prevention

    Risk Factor Modification: Exercise and Healthy Diet

    Diagnosis

    Metabolic Syndrome Components: Abdominal Adiposity

    Overview of Heart Failure

    Heart Failure Diagnostic Criteria - Diagnostic Criteria

    Association Between Atrial Fibrillation and Heart Failure

    Pathophysiological Cycle

    Treatment

    Pharmacotherapy - Bile Acid Resins

    Overview of Pulmonary Arterial Hypertension

    Introduction: PAH

    Treatment and Prevention of Cancer-associated VTE

    Outpatients receiving chemotherapy: Preventive Therapy Trials

    Treatment and Prevention of Cancer-associated VTE

    Anticoagulant Treatment and Survival

    Monoclonal Antibodies

    Production of Monoclonal Antibodies by Hybridomas
    Production of Monoclonal Antibodies in Mammal...

    VTE Clinical Picture: Natural History, Clinical Syndromes, Complications

    Natural History of VTE

    Atherothrombosis

    Overview: Atherothrombosis
    Interactivity: Unstable Plaque
    Interactivity: Thrombus Formatio...

    Introduction to Monoclonal Antibodies

    Naming Monoclonal Antibodies: Pali-vi-zu-mab

    Patient History

    Neurological History
    Presenting Symptoms in MS Patients

    The Nervous System

    The CNS: Brain

    Diagnosis of SLE

    Standard Measures of Disease Activity Used in Clinical Trials: SLICC/ACR Damage Index for SLE

    Diabetes Clinical Trials Studying Complications

    DCCT/EDIC Study

    Adult and Late-Onset Hypogonadism

    Overview: Adult and Late-Onset Hypogonadism

    Definition and Classification

    History and Controversy: Syndrome X and WHO Definition

    Epidemiology

    Incidence and Prevalence: National Health and Nutrition Examination Survey

    Epidemiology

    Risk Factors - Genetic Predisposition

    Pathophysiology

    Retinopathy

    Diagnosis

    Metabolic Syndrome Components: Dyslipidemia and Blood Pressure

    Overview of Heart Failure

    Overview of Heart Failure (HF)

    Overview of Heart Failure

    Heart Failure Diagnostic Criteria - Signs and Symptoms

    Diagnosis and Classification

    Diagnosis and Classification

    Management of Hypertension

    Drug Combinations

    Treatment

    AACE Guidelines

    Treatment

    Pharmacotherapy - Cholesterol Absorption Inhibitor

    Treatment

    Pharmacotherapy - Niacin

    Pathophysiologic Mechanisms

    Pathophysiologic Mechanisms

    Diagnosis and Prognosis

    Diagnosis and Prognosis

    Incidence and Risk of VTE in Cancer Patients

    Risk Factors for Cancer-associated VTE

    Risk Assessment, Diagnosis, and Prognosis of Cancer-associated VTE

    Prognosis and Risk Factors of Cancer-associated VTE

    Treatment and Prevention of Cancer-associated VTE

    Outpatients receiving chemotherapy: Agnelli et al, 2009

    Treatment and Prevention of Cancer-associated VTE

    Prevention of VTE Recurrence

    Summary: Binge Eating Disorder (BED) Disease State

    Summary: Binge Eating Disorder (BED) Disease State

    T2DM Diagnosis

    Signs and Symptoms

    Pathology of T2DM

    Fat Cells: Increased FFAs, Excess Lipids

    Management

    Treatment Goals and Guidelines

    Stroke Prevention Key Concepts

    Summary: Stroke Prevention Key Concepts

    Definition of Atrial Fibrillation

    Atrial Fibrillation Definition

    Thromboembolic Complications

    Myocardial and Hemodynamic Consequences: Overview

    Measures of Platelet Aggregation

    Overview: Platelets
    VerifyNow: Overview
    VerifyNow: P2Y12 Cartridge
    VerifyNow: PRU: P2...

    Economic Burden of AF

    Overview and Estimating Healthcare Costs Attributable to AF

    Special Populations

    NLA: Women

    Epidemiology and Risk Factors

    Risk Factors and Ischemic Stroke

    Monoclonal Antibodies

    Naming Monoclonal Antibodies

    The Nervous System

    The Central Nervous System (CNS)
    The CNS: Brain

    Introduction: Clinical Presentation of Lupus

    Introduction: Clinical Presentation of Lupus

    Diabetes Clinical Trial Design: Cohort Designs

    Cohort Study

    Microvascular Complications

    Diabetic Neuropathy: Pathogenesis

    Hypersensitivity

    Type I Hypersensitivity Reaction: Immediate Hypersensitivity
    Hypersensitivity Disorders: Type 1...

    Diagnosis of Kidney Disease

    Diagnosis: Patient History, Physical Examination and Urinalysis

    Introduction to Kidney Disease

    Diabetic Nephropathy (DN)

    Disease State

    Signs and Symptoms

    Diabetic Nephropathy

    Description: Diabetic Kidney Disease (DKD)

    Overview: Angiogenesis

    Functions of Angiogenesis

    Phase III Data: ENGAGE AF-TIMI 48

    Phase III Data: ENGAGE AF-TIMI 48: Study Overview

    Pathophysiology

    Nephropathy

    Pathophysiology

    Neuropathy

    Diagnosis

    Hyperglycemia and Diabetes

    Overview of Heart Failure

    Classification of Heart Failure: NYHA Functional Classification

    Overview of Heart Failure

    Heart Failure Diagnostic Criteria - Imaging

    Overview of Heart Failure

    Heart Failure Diagnostic Criteria - Laboratory Tests

    Association Between Atrial Fibrillation and Heart Failure

    Prognostic Significance of AF in Patients with HF

    Definitions of Hypertension

    Hypertension or High Blood Pressure

    Disease State

    Definition and Classification

    Treatment

    Pharmacotherapy - Fibrates

    Treatment

    Special Populations with Hyperlipidemia

    Epidemiology and Risk Factors for PAH

    Epidemiology and Risk Factors for PAH

    Pathophysiologic Mechanisms

    Overview of Vascular Smooth Muscle Cell Contraction

    Diagnosis and Prognosis

    Confirmation with Complete Right Heart Catheterization

    Diagnosis and Prognosis

    Natural History

    Therapy

    Therapy and Goals of Treatment

    Therapy

    Combination Therapy

    Overview: Cancer VTE

    VTE and Cancer

    Incidence and Risk of VTE in Cancer Patients

    Assessing Impact of Treatment on VTE Risk From Observational vs. Randomized Controlled Studies

    Risk Assessment, Diagnosis, and Prognosis of Cancer-associated VTE

    Diagnosis of Cancer-associated VTE: Wells Score

    Treatment and Prevention of Cancer-associated VTE

    VTE Therapeutic Agents

    Summary: Cancer-associated VTE

    Summary: Cancer-associated VTE

    Epidemiology and Natural History

    Natural History

    Anxiety Disorders Disease: Introduction

    Prevalence of Anxiety Disorders

    Impact of Diabetes

    Deaths Attributable to Disease
    4 Out of 5 People with Diabetes Live in Low and Middle Income Co...

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Antithrombotic Therapy for Atrial Fibrillation, Switching Warfarin Formulations, Kwong et al., 2012

    Special Populations

    NLA: South Asians

    Special Populations

    NLA: American Indians/Alaska Natives

    Cardiac Cycle

    Overview
    Pressure and Volume: Rapid Ejection
    Pressure and Volume: Reduced Ejection
    Pr...

    Effects of Vascular Injury

    Blood Clot Formation

    Phase I Data: Drug-Drug Interaction Data

    Drug-Drug Interactions: Overview

    Diagnosis of SLE

    Standard Measures of Disease Activity Used in Clinical Trials: SLEDAI-2K
    Standard Measures of D...

    Epidemiology of Diabetes

    Impact of Diabetes
    Effect of Type 2 Diabetes and Obesity on Quality of Life Score
    Diabetic...

    Introduction: Pathology of Diabetes Complications

    Chronic Diabetes Complications: Macrovascular and Diabetic Foot

    Psoriasis Therapies

    Systemic Therapies: Retinoids
    Retinoids: Mechanism of Action
    Retinoids: Clinical Efficacy

    What is the Role of Toxicology in Drug Development?

    How Does Toxicology Relate to the Pre-Clinical Road Map?
    Safety Pharmacology
    In Vivo and I...

    Diabetic Nephropathy

    Kidney Disease Treatment: Goals and Components

    Basal Insulin: Degludec

    Basal Insulin Analog: Insulin Degludec

    Definition and Classification

    Spectrum of Disorders

    Definition and Classification

    History and Controversy: Harmonizing the Metabolic Syndrome

    Therapeutic Considerations

    Other Pharmacologic Therapy

    Resistant Hypertension

    Types of Hypertension

    Disease State

    Basic Lipid Biochemistry

    Disease State

    Etiology of Hyperlipidemia

    Epidemiology

    Epidemiology, Incidence and Prevalence

    Diagnosis and Monitoring

    Diagnostic Tests

    Pathophysiologic Mechanisms

    Overview of Blood Vessel Architecture

    Therapy

    Pathway-Specific Approaches

    Overview: Cancer VTE

    Venous Thromboembolism (VTE) Overview

    Incidence and Risk of Cancer in VTE Patients

    Incidence of Cancer in VTE Patients

    Incidence and Risk of VTE in Cancer Patients

    Incidence of VTE in Cancer Patients

    Incidence and Risk of VTE in Cancer Patients

    Cancer-related Risk Factors

    Incidence and Risk of VTE in Cancer Patients

    Mechanisms Underlying Cancer-associated VTE

    Risk Assessment, Diagnosis, and Prognosis of Cancer-associated VTE

    Risk Assessment Tools

    Treatment and Prevention of Cancer-associated VTE

    Guidelines for VTE Prevention and Treatment

    BED Disease State

    Diagnostic Criteria, Disease Onset, and Clinical Course

    Neurology/Major Depressive Disorder Disease: Introduction

    Major Depressive Disorder (MDD)

    Clinical Implications of Clot Formation

    Thrombosis

    Special Populations

    NLA: African Americans

    Monoclonal Antibodies

    Monoclonal Antibody Production
    Monoclonal Antibody Production: Knowledge Check

    Development of Monoclonal Antibodies

    Monoclonal Antibody Production in Hybridomas
    Monoclonal Antibody Production in CHO Cells
    M...

    Clinical Trials Comparing GLP-1 Receptor Agonists

    Comparison of GLP-1 Receptor Agonists

    HAART-Associated Adverse Clinical Events

    HAART-Associated Adverse Clinical Events
    Lactic Acidosis
    Liver Toxicity
    Glucose Intol...

    Osteoporosis and Obesity

    Background

    Measures of Kidney Function

    Blood Urea Nitrogen (BUN), Urine Protein, and Possible Causes of Proteinurina

    Phase III Data: Hokusai-VTE

    Methods: Patient Population

    Overview of Heart Failure

    Classification of Heart Failure: Conventional Classification

    Epidemiology of Heart Failure

    Risk Factors for HF

    Therapeutic Considerations

    Therapeutic Considerations: Overview

    Epidemiology

    Epidemiology

    Causes of Secondary Hypertension

    Causes of Secondary Hypertension

    Management of Hypertension

    Hypertension Management Guidelines

    Treatment

    Pharmacotherapy - Statins

    Epidemiology and Risk Factors

    Epidemiology

    Epidemiology and Risk Factors for PAH

    Risk Factors

    Pathophysiologic Mechanisms

    Specific Mediators

    Effects of Opioids

    Effects of Opioids

    Management

    Goals of Treatment

    Special Populations

    Special Populations: Introduction

    Systemic Therapy

    Systemic Therapy: Purpose

    Monoclonal Antibodies

    Monoclonal Antibody Production

    Glycemic Endpoint Studies

    Dulaglutide Glycemic Endpoint Trials: Umpierrez et al. EGO Study

    Atopy vs. Allergy

    Hypersensitivity Disorders

    Association Between Atrial Fibrillation and Heart Failure

    AF and HF: Overview

    Etiology of Hypertension

    Risk Factors

    Pathophysiology

    Pathophysiology

    Overview of Pulmonary Arterial Hypertension

    Overview of Pulmonary Arterial Hypertension

    Diagnosis and Prognosis

    Pivotal Tests

    Annotate: Hokusai

    Hokusai-VTE Trial

    Pathology of T2DM

    Insulin Resistance: Hepatic (Liver)
    Decreased Glucose Uptake (Muscle)
    Decreased Insulin Se...

    Guidelines for Anticoagulant Therapy

    Atrial Fibrillation (AF): Stroke Risk

    Clopidogrel Clinical Trials

    CAPRIE: Conclusion

    Clopidogrel Clinical Trials

    COMMIT Study

    Plavix® vs. Effient™

    Variability of Response: IPA Link to Clinical Outcomes

    Hypersensitivity

    Type IV Hypersensitivity Reaction Subgroups
    Gell-Coombs Classification
    Type I Hypersensiti...

    Epidemiology of Heart Failure

    Epidemiology of HF: Overview

    Management of Hypertension in Special Populations

    Management of Hypertension in Special Populations

    Management of Hypertension

    Medications

    Diagnosis

    Physical Examination: Other

    Annotate: ENGAGE

    Edoxaban versus Warfarin in Patients with Atrial Fibrillation

    Diabetes Annotations

    Jardiance

    Clopidogrel Clinical Trials

    CLARITY Study

    Thienopyridines

    Approved Indications

    Psoriatic Arthritis Therapies

    Symptomatic Treatment
    Symptomatic Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

    Psoriatic Arthritis Therapies

    Symptomatic Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

    NSAIDs

    Introduction: NSAIDs

    Diabetes Annotations

    Abasaglar insulin glargine

    Standard Agents: Therapeutic Challenges

    Unfractionated Heparin: Warnings and Precautions

    Physical Exam

    Physical Examination: Other

    SLE Treatments: NSAIDs

    Main Types of NSAIDs

    SLE Treatments: NSAIDs

    Main Types of NSAIDs
    Mode of Action
    Indicated for Use in SLE

    Diabetes Annotations

    AWARD-2 Study

    Kidney Function: GFR

    Measure of Kidney Function

    Macrovascular Complications

    Chronic Diabetes Complications: Macrovascular

    Signs and Symptoms

    Damage to Specific CNS Regions

    Epidemiology

    Mortality and Survival

    Adult and Late-Onset Hypogonadism

    Comorbidities: Overview

    Mendelian Genetics

    Mendelian Genetics and History of Cholesterol and Atherosclerosis

    Combination Product Regulation

    Combination Products: Approval as Drug or Device

    Signs and Symptoms

    Signs and Symptoms Overview: Impact on the Patient
    Damage to Specific CNS Regions
    Damage t...

    Monitoring

    Compliance Toxicities
    Patient Compliance
    Toxicity

    Monitoring

    Toxicity

    Clinical Trials: Event Definitions

    Analyzing the Results of Diabetes Trials: Relative Risk

    Infliximab

    Pivotal Trials: Efficacy of Maintenance
    Infliximab Safety

    Infliximab

    Infliximab Safety

    Aspirin and Primary Stroke Prevention

    Clinical Trials and Meta-analysis Data

    Epidemiology

    Longitudinal Studies: Age-Associated Diseases

    Overview of Obesity

    Health Consequences of Overweight and Obesity

    Diagnosis

    History: Presenting Symptoms in MS Patients

    Health Outcomes

    Dulaglutide: AWARD-1 Reaney M., et al., 2013

    Management

    Goals of Treatment

    Overview of Obesity

    Overweight/Obese Defined
    Body Mass Index
    Waist Circumference and Obesity
    Cause of Obe...

    Current Therapies

    Symptomatic Therapies

    SLE Treatments: MAbs/Biologics

    Belimumab Clinical Trials 2 and 3: Efficacy
    Belimumab Clinical Trials 2 and 3: Warnings and Pre...

    SLE Treatments: MAbs/Biologics

    Belimumab Clinical Trials 2 and 3: Warnings and Precautions

    Complications of RA

    Major Organs Affected by RA

    T1DM (Type 1 Diabetes)

    Incidence of T1DM Varies with Race

    Diagnosis

    Overview: The Challenge of Diagnosis
    Physical Examination: Motor
    Physical Examination: Oth...

    Steroids

    Glucocorticoids: Mode of Action
    The Anti-Inflammatory Effects of Corticosteroids
    Glucocort...

    Steroids

    Glucocorticoids: Side Effects

    Typical Course of Plaque Psoriasis

    Onset, Episodes, Flare-Ups, Triggers
    Complications and Comorbidities of Psoriasis

    Typical Course of Plaque Psoriasis

    Complications and Comorbidities of Psoriasis

    Emerging Hypotheses on Treatment

    Immunological Concepts: Oral Immune-Modulating Drugs

    Criteria for the Diagnosis of Dementia Due to Alzheimer's Disease

    Differential Diagnosis

    Visualization

    Acute Ischemic Stroke: Thrombolysis

    Background

    Tissue Plasminogen Activator (tPA)

    Visualization: The NINDS Study

    NINDS Study

    Stroke: NIHSS Criteria

    Cohort Studies: Background
    Modified Rankin Score
    NIHSS Criteria

    Stroke: NIHSS Criteria

    Cohort Studies: Background

    Stroke: NIHSS Criteria

    Modified Rankin Score

    Stroke: NIHSS Criteria

    NIHSS Criteria

    Background

    Clinical Trials

    Background

    Thrombolytic Therapy

    Stroke Outcome Measures

    Barthel Index
    Modified Rankin Score
    Glasgow Outcome Scale
    NIHSS Criteria

    Stroke Outcome Measures

    Barthel Index

    Stroke Outcome Measures

    Modified Rankin Score

    Stroke Outcome Measures

    Glasgow Outcome Scale

    Stroke Outcome Measures

    NIHSS Criteria

    Background

    Penumbra

    Rationale For Use of Novel Oral Anticoagulants

    Overview of Anticoagulant Agents

    Rationale For Use of Novel Oral Anticoagulants

    Limitations of Traditional Rapid Acting and Oral Anticoagulants

    Rationale For Use of Novel Oral Anticoagulants

    Development, Advantages and Limitations of Novel Oral Anticoagulants

    Rationale For Use of Novel Oral Anticoagulants

    Use of Anticoagulants and FDA Approved Novel Oral Anticoagulants

    Use of Novel Oral Anticoagulants

    Stroke Prevention in Atrial Fibrillation

    Use of Novel Oral Anticoagulants

    Acute Coronary Syndrome (ACS)

    Use of Novel Oral Anticoagulants: Overview

    Use of Novel Oral Anticoagulants: Overview

    Novel Oral Anticoagulant (NOAC) Targets

    Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

    Dabigatran: Overview, Indications, Dosage and Administration

    Introduction: Hemostasis and Bleeding Management

    Introduction: Hemostasis and Bleeding Management

    Introduction

    Clot Formation

    Clot Formation: Coagulation

    Clinical Implications of Clot Formation

    Arterial Thrombosis

    Clinical Implications of Clot Formation

    Atrial Fibrillation and Venous Thrombosis

    Patient Types and Risk Factors for Bleeding

    Bleeding Disorders

    Bleeding Risk Stratification

    Bleeding Risk Schemes: Overview

    Bleeding Risk Stratification

    Bleeding Risk Stratification Schemes

    Laboratory Monitoring of Patients at Risk of Thrombosis or Bleeding

    Overview: Complete Blood Count, Fecal Occult Blood Test and Other Laboratory Tests

    Laboratory Monitoring of Patients at Risk of Thrombosis or Bleeding

    Laboratory Tests of Patients at Risk of Thrombosis or Bleeding

    Patient Education

    Patient Involvement, Compliance and Education

    Treatment of Bleeding

    Overview: Basic Management of Bleeding

    Anticoagulant Reversal

    Overview: Anticoagulant Reversal Agents

    Anticoagulant Reversal

    Factor VIII Inhibitor Bypass Activity (FEIBA)

    Standard Agents: Therapeutic Challenges

    Enoxaparin: Contraindications and Dalteparin: Warnings and Precautions

    Introduction

    Introduction

    Introduction

    Introduction

    Guidelines for Prophylactic Anticoagulant Therapy

    Prevention in Surgical Patients Non-Orthopedic Surgery: American College of Chest Physicians (ACCP) ...

    Guidelines for Prophylactic Anticoagulant Therapy

    Prevention in Surgical Patients Non-Orthopedic Surgery

    Guidelines for Prophylactic Anticoagulant Therapy

    Prevention in Surgical Patients and Orthopedic Surgery

    Guidelines for Prophylactic Anticoagulant Therapy

    VTE Prevention in Medical Patients: Increased Risk for VTE

    Introduction

    Introduction

    Guidelines for Prophylactic Anticoagulant Therapy

    Overview of Anticoagulation Therapy

    Guidelines for Prophylactic Anticoagulant Therapy

    Atrial Fibrillation Overview

    Guidelines for Prophylactic Anticoagulant Therapy

    Atrial Fibrillation Stroke Risk

    Guidelines for Prophylactic Anticoagulant Therapy

    Risk of Thromboembolism

    Guidelines for Prophylactic Anticoagulant Therapy

    Guidelines for Anticoagulation Therapy

    Guidelines for Prophylactic Anticoagulant Therapy

    Venous Thromboembolism (VTE) Prophylaxis

    Guidelines for Prophylactic Anticoagulant Therapy

    VTE Prevention in Medical Patients

    Guidelines for Prophylactic Anticoagulant Therapy

    ACCP, AAOS, ASRA Compendium of Consensus Recommendations for VTE Prophylaxis

    Guidelines for Prophylactic Anticoagulant Therapy

    Prevention in Surgical Patients and Orthopedic Surgery: American College of Chest Physicians Guideli...

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Venous Thromboembolism Overview

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Pulmonary Embolism

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Pulmonary Embolism Treatment

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Venous Thromboembolism Treatment

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Venous Thromboembolism Treatment: Uncomplicated Initial Treatment

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Venous Thromboembolism Treatment: Complications or Comorbidities

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Venous Thromboembolism Treatment: Complications During Therapy

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Venous Thromboembolism Treatment: ACCP Treatment Guidelines

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Follow-Up and Secondary Prevention - Duration of Treatment

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Follow-Up and Secondary Prevention: Bridging and Perioperative Management

    Guidelines for Anticoagulant Venous Thromboembolism Therapy

    Follow-Up and Secondary Prevention - Chronic Thromboembolic Pulmonary Hypertension

    Standard Agents: Overview

    Standard Anticoagulants

    Standard Agents: Overview

    Vitamin K Antagonists (VKAs)

    Standard Agents: Overview

    Aspirin: Overview

    Standard Agents: Overview

    Aspirin: Mechanism of Action

    Standard Agents: Overview

    Unfractionated Heparin: Overview

    Standard Agents: Overview

    Low-Molecular-Weight Heparin (LMWH)

    Standard Agents: Overview

    Low-Molecular-Weight Heparin (LMWH): Dosage and Administration

    Standard Agents: Overview

    Fondaparinux: Overview

    Standard Agents: Clinical Studies

    Standard Agents: Clinical Studies

    Vitamin K Antagonists (VKAs): Warfarin

    Standard Agents: Clinical Studies

    Vitamin K Antagonists (VKAs) Warfarin: Acute Venous Thromboembolism (VTE)

    Standard Agents: Clinical Studies

    Vitamin K Antagonists (VKAs) Warfarin: ACCP CHEST Guidelines

    Standard Agents: Overview

    Vitamin K Antagonists (VKAs) Warfarin: Venous Thromboembolism (VTE)

    Standard Agents: Clinical Studies

    Aspirin

    Standard Agents: Clinical Studies

    Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparins (LMWHs)

    Standard Agents: Clinical Studies

    Recurrent Venous Thromboembolism (VTE)

    Standard Agents: Clinical Studies

    Fondaparinux: Clinical Studies

    Standard Agents: Therapeutic Challenges

    Therapeutic Challenges of Antithrombotic Treatment

    Standard Agents: Therapeutic Challenges

    Vitamin K Antagonists (VKAs): Warfarin Contraindications

    Standard Agents: Therapeutic Challenges

    Vitamin K Antagonists (VKAs): Warfarin Special Considerations and Drug Interactions

    Standard Agents: Therapeutic Challenges

    Vitamin K Antagonists (VKAs): Warfarin Monitoring and Warfarin Anticoagulant Reversal

    Standard Agents: Therapeutic Challenges

    Aspirin: Warnings and Precautions

    Standard Agents: Therapeutic Challenges

    Aspirin: Anticoagulant Reversal

    Standard Agents: Therapeutic Challenges

    Unfractionated Heparin: Contraindications, Monitoring and Anticoagulation Reversal

    Standard Agents: Therapeutic Challenges

    Enoxaparin and Dalteparin: Boxed Warning

    Standard Agents: Therapeutic Challenges

    Enoxaparin: Warnings and Precautions

    Standard Agents: Therapeutic Challenges

    Dalteparin Contraindications and Laboratory Monitoring

    Standard Agents: Therapeutic Challenges

    Fondaparinux: Boxed Warning

    Standard Agents: Therapeutic Challenges

    Fondaparinux: Warnings and Precautions

    Standard Agents: Therapeutic Challenges

    Fondaparinux: Contraindications, Laboratory Monitoring and Anticoagulant Reversal

    Table of Agents for Review

    Table of Agents for Review

    Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

    Direct Thrombin Inhibitors: Mechanism of Action and Clinical Pharmacology

    Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

    Dabigatran: Special Considerations

    Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

    Dabigatran: Contraindications, Warnings and Precautions

    Novel Oral Anticoagulants: Direct Thrombin Inhibitors - Dabigatran

    Dabigatran: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

    Rivaroxaban: Overview, Indications, Dosage and Administration

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

    Rivaroxaban: Mechanism of Action and Clinical Pharmacology

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

    Rivaroxaban: Special Considerations, Contraindications and Boxed Warning

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

    Rivaroxaban: Warnings and Precautions

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Rivaroxaban

    Rivaroxaban: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

    Apixaban: Overview, Dosage and Administration

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

    Apixaban: Mechanism of Action and Clinical Pharmacology

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

    Apixaban: Special Considerations

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

    Apixaban: Contraindications and Boxed Warning

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

    Apixaban: Warning and Precautions

    Novel Oral Anticoagulants: Factor Xa Inhibitors - Apixaban

    Apixaban: Use in Pregnancy, Laboratory Monitoring and Anticoagulant Reversal

    Novel Oral Anticoagulants: Factor Xa Inhibitors

    Emerging Factor Xa Inhibitors: Edoxaban and Betrixaban

    Summary of Agents

    Table of Agents for Review

    Learning Objectives

    Learning Objectives

    Dabigatran Clinical Trials: Atrial Fibrillation

    Dabigatran Clinical Trials

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY Study

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY: Study Population Results

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY Results: Primary Outcome Stroke or Systemic Embolism

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY Results: Secondary Outcome Stroke

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY Results: Other Outcomes

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY Results: Primary Safety Outcome Major-Bleeding, Dabigatran vs. Warfarin

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY-ABLE

    Dabigatran Clinical Trials: Atrial Fibrillation

    RELY-ABLE Trial

    Dabigatran Clinical Trials: Venous Thromboembolism

    RECOVER Trial

    Dabigatran Clinical Trials: Venous Thromboembolism

    RECOVER: Study Population Results

    Dabigatran Clinical Trials: Venous Thromboembolism

    RECOVER: Primary and Secondary Efficacy Results

    Dabigatran Clinical Trials: Venous Thromboembolism

    RECOVER: Results Summary

    Dabigatran Clinical Trials: Venous Thromboembolism

    REMEDY and RESONATE Trials

    Dabigatran Clinical Trials: Acute Coronary Syndrome

    REDEEM Trial

    Dabigatran Clinical Trials: Acute Coronary Syndrome

    REDEEM Trial: D-dimer Concentrations

    Dabigatran Clinical Trials: Acute Coronary Syndrome

    Development Programs: RE-ALIGN Heart Valves

    Dabigatran Clinical Trials: Summary

    Dabigatran Clinical Trials: Summary

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    Rivaroxaban Clinical Trials: Overview

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    ROCKET Atrial Fibrillation: Baseline Characteristics Results

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    ROCKET Atrial Fibrillation: Primary Efficacy Results

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    ROCKET Atrial Fibrillation: Primary Efficacy Events During Transition to Open-Label Therapy

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    ROCKET Atrial Fibrillation: Secondary Efficacy Outcomes

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    ROCKET Atrial Fibrillation: Results Summary

    Rivaroxaban Clinical Trials: Atrial Fibrillation

    XANTUS Study

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-DVT Study

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-DVT: Baseline Characteristic Results

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-DVT: Primary Efficacy Results

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-DVT: Primary Efficacy Results Time Course

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-DVT: Safety Results

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-DVT: Net Clinical Benefit and Summary

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-PE Trial

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-PE: Baseline Characteristics Results

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-PE: Primary Efficacy Results

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-PE: Primary Efficacy Results Time Course

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-PE: Safety Results

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-PE: Net Clinical Benefit and Summary

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    EINSTEIN-EXT Study

    Rivaroxaban Clinical Trials: Venous Thromboembolism

    XALIA Study

    Rivaroxaban Clinical Trials: Acute Coronary Syndrome

    X-PLORER Study

    Rivaroxaban Clinical Trials: Overview of Other Development Programs

    Development Programs: Rivaroxaban

    Rivaroxaban Clinical Trials: Summary

    Rivaroxaban Clinical Trials: Summary

    Apixaban Clinical Trials: Atrial Fibrillation

    Apixaban Clinical Trials

    Apixaban Clinical Trials: Atrial Fibrillation

    AVERROES Study

    Apixaban Clinical Trials: Atrial Fibrillation

    ARISTOTLE Trial

    Apixaban Clinical Trials: Atrial Fibrillation

    ARISTOTLE: Baseline Characteristics Results

    Apixaban Clinical Trials: Atrial Fibrillation

    ARISTOTLE: Efficacy Results

    Apixaban Clinical Trials: Atrial Fibrillation

    ARISTOTLE: Safety Results

    Apixaban Clinical Trials: Atrial Fibrillation

    ARISTOTLE: Results Summary

    Apixaban Clinical Trials: Venous Thromboembolism

    AMPLIFY Study: Baseline Characteristics Results and Primary Efficacy Results

    Apixaban Clinical Trials: Venous Thromboembolism

    AMPLIFY Study: Safety Results

    Apixaban Clinical Trials: Venous Thromboembolism

    AMPLIFY Study: Results Summary

    Apixaban Clinical Trials: Venous Thromboembolism

    AMPLIFY-EXT Study

    Apixaban Clinical Trials: Overview of Other Development Programs

    Development Programs: Overview

    Apixaban Clinical Trials: Summary

    Apixaban Clinical Trials: Summary

    Introduction

    Introduction

    Economic Burden of AF

    Cost of AF from a Payer Perspective

    Economic Burden of Stroke

    Overview: Strokes in AF

    Economic Burden of Stroke

    Stroke Risk Based Upon Anticoagulation Use

    Economic Burden of Stroke

    Cost Based Upon Anticoagulation Use

    Economic Burden of Bleeding

    Overview: Antithrombotic Therapy for Atrial Fibrillation

    Economic Burden of Bleeding

    Mercaldi and Associates Study

    Economic Burden of Bleeding

    Per Patient Cost of Bleeding

    Economic Burden of Bleeding

    Ghate and Coworkers Analysis

    Economic Burden of Bleeding

    Summary of Costs for AF, Stroke and Bleeding

    Comorbidities and Health-Related Quality of Life in Patients with AF

    Comorbidities Commonly Associated with AF

    Comorbidities and Health-Related Quality of Life in Patients with AF

    Comorbidities Commonly Associated with AF: Wu et al., 1995

    Comorbidities and Health-Related Quality of Life in Patients with AF

    Health-Related Quality of Life (HRQoL) in AF Patients

    Comorbidities and Health-Related Quality of Life in Patients with AF

    Health-Related Quality of Life Studies in Atrial Fibrillation

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Kwong and Associates Study

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Methods Patient Population, Study Design and Endpoints

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Results: Patient Population

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Results: Health Care Resource Use Analysis

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Results: Health Care Resource Use Analysis, Controlled for variables

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Results: Health Care Cost Analysis - Unadjusted Costs

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Results: Health Care Cost Analysis - Generic vs. Brand-Only

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Conclusion: Use and Costs Associated with Switching Warfarin

    Resource Use and Costs Associated with Switching Warfarin in AF Patients

    Table Summary of Kwong et. al, 2012

    Economic Burden of VTE

    Overview of VTE

    Economic Burden of VTE

    Total Cost of VTE

    Economic Burden of VTE

    Per Patient Cost of DVT and PE

    Economic Burden of VTE

    Per Patient Cost of Recurrent VTE

    Economic Burden of VTE

    Incremental Cost of Recurrent VTE

    Economic Burden of VTE

    Summary of Costs for VTE

    VTE Comorbidities and Health-Related Quality of Life

    Overview and Incidence of VTE

    VTE Comorbidities and Health-Related Quality of Life

    VTE Prevalence Increases with Age

    VTE Comorbidities and Health-Related Quality of Life

    Projected VTE Prevalence Increases with Time

    VTE Comorbidities and Health-Related Quality of Life

    Comorbidities Commonly Associated with VTE

    VTE Comorbidities and Health-Related Quality of Life

    Risk Factors for VTE

    VTE Comorbidities and Health-Related Quality of Life

    Health-Related Quality of Life (HRQoL) in VTE Patients

    VTE Comorbidities and Health-Related Quality of Life

    Health-Related Quality of Life (HRQoL) in VTE Patients: Acute Deep Vein Thrombosis

    VTE Comorbidities and Health-Related Quality of Life

    Health-Related Quality of Life (HRQoL) in VTE Patients: Post-Thrombotic Syndrome

    Cost-Effective Analyses Overview

    Cost-Effective Analyses Overview

    Cost-Effective Analyses Overview

    Cost-Effective Analyses (CEAs)

    Cost-Effectiveness Studies: Harrington et al., 2013

    Harrington Study: Warfarin Compared to NOACs

    Cost-Effectiveness Studies: Harrington et al., 2013

    Study Overview: Harrington et al.

    Cost-Effectiveness Studies: Harrington et al., 2013

    Methods Patient Population

    Cost-Effectiveness Studies: Harrington et al., 2013

    Methods Study Design

    Cost-Effectiveness Studies: Harrington et al., 2013

    Methods Endpoints

    Cost-Effectiveness Studies: Harrington et al., 2013

    Harrington Study: Results

    Cost-Effectiveness Studies: Harrington et al., 2013

    Harrington Study: Conclusions

    Cost-Effectiveness Studies: Kansal et al., 2013

    Overview: Kansal Study

    Cost-Effectiveness Studies: Kansal et al., 2013

    Kansal Study: Study Overview

    Cost-Effectiveness Studies: Kansal et al., 2013

    Kansal Study: Methods and Literature Search Strategy

    Cost-Effectiveness Studies: Kansal et al., 2013

    Kansal Study: Results

    Cost-Effectiveness Studies: Kansal et al., 2013

    Results: Cost-Effectiveness of Factor Xa Inhibitors

    Cost-Effectiveness Studies: Kansal et al., 2013

    Kansal Study: Conclusions

    Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

    Mahmoudi and Sobieraj Study: Overview

    Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

    Mahmoudi and Sobieraj Study: Study Overview

    Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

    Methods: Cost-Effectiveness Model

    Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

    Methods: Studies Included in the Analysis and Quality-of-Life Measures

    Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

    Methods Endpoints: Costs

    Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

    Results: Base-Case Analysis and Conclusion

    Cost-Effectiveness Studies: Mahmoudi and Sobieraj, 2013

    Summary of Cost-Effectiveness Studies

    Overview of the Pathophysiology of Arthrosclerosis/CVD: Introduction

    Overview of the Pathophysiology of Arthrosclerosis

    Overview of Atherothrombosis

    Virchow's Triad

    Overview of Atherothrombosis

    Arterial Thrombosis

    Pathogenesis of Atherogenesis

    Atherogenesis

    Pathogenesis of Atherogenesis

    Involvement of Platelets

    Risk Factors for CHD and MI

    Risk Factors

    Basic Lipid Biochemistry

    Basic Lipid Biochemistry

    Basic Lipid Biochemistry

    Lipid Transport System

    Basic Lipid Biochemistry

    Cholesterol Regulation

    Dyslipidemia Disease State

    Definition and Classification of Dyslipidemia

    Dyslipidemia Disease State

    Etiology of Secondary Dyslipidemia

    Epidemiology

    Epidemiology

    Treatment Options: Introduction and Overview

    Treatment Options: Introduction and Overview

    Treatment Options: Learning Objectives

    Treatment Options: Learning Objectives

    Statins

    Chemical Structure

    Statins

    Mechanism of Action

    Statins

    Dosing and Administration

    Statins

    Side Effects

    Statins

    Statin Intolerance

    Statins

    Efficacy and Safety: Therapy Results

    Statins

    Efficacy and Safety: Special Populations

    Ezetimibe (Zetia)

    FDA Approval, 2002

    Ezetimibe (Zetia)

    Efficacy and Safety: Monotherapy

    Ezetimibe (Zetia)

    Efficacy and Safety: Ezetimibe Plus Statins

    Ezetimibe (Zetia)

    Efficacy and Safety: SHARP (Study of Heart and Renal Protection - 2011)

    PCSK9 Inhibitors

    Side Effects

    Niacin (Nicotinic Acid)

    Chemical Structure

    Niacin (Nicotinic Acid)

    Side Effects and Contraindications

    Niacin (Nicotinic Acid)

    Efficacy and Safety: Word of Caution

    Fibrates

    Chemical Structure, MoA, and Administration: Fibrates

    Fibrates

    Patient Benefit

    MTP and Oligonucleotide Inhibitors

    Lomitapide

    MTP and Oligonucleotide Inhibitors

    Side Effects: Lomitapide and Mipomersen

    MTP and Oligonucleotide Inhibitors

    Efficacy, Safety, Meta-analysis

    Bile Acid Sequestrants

    Available Bile Acid Sequestrants (Bile Acid Binding Resins)

    Emerging Therapies

    Emerging Therapies Overview

    Emerging Therapies

    Still in Development: Anacetrapib and TA-8995

    Emerging Therapies

    Emerging Therapies that Target PCSK9

    Emerging Therapies

    Emerging Therapies: ETC-1002 (Bempedoic Acid)

    Emerging Therapies

    Emerging Therapies that Target Lp(A)

    Treatment Guidelines: Introduction

    Treatment Guidelines: Learning Objectives

    Treatment Goals and Modalities

    AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

    Treatment Goals and Modalities

    AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis Overview

    AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

    Dyslipidemia and Prevention of Atherosclerosis

    AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

    Screening

    AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

    Follow-Up and Monitoring

    Additional Recommendations and Position Statements

    National Lipid Association (NLA) Recommendations for Patient-Centered Management of Dyslipidemia

    Additional Recommendations and Position Statements

    NLA Recommendations for Patient-Centered Management of Dyslipidemia

    Additional Recommendations and Position Statements

    NLA Recommendations for Patient-Centered Management of Dyslipidemia: Lipoprotein Levels

    Clopidogrel Clinical Trials

    ISAR CHOICE Study

    Clopidogrel

    Clopidogrel: Mechanism of Action

    Introduction

    Thienopyridines: Introduction

    Clopidogrel Clinical Trials

    ALBION Study

    Clopidogrel

    Clopidogrel: Approved Indications

    Clopidogrel Clinical Trials

    ARMYDA-2 Study

    Clopidogrel Clinical Trials

    CURRENT-OASIS 7: Results

    Clopidogrel Clinical Trials

    CURRENT-OASIS 7 Study

    Learning Objectives

    Clopidogrel Clinical Trials

    Pretreatment Study

    Clopidogrel Clinical Trials

    CREDO Study

    Clopidogrel Clinical Trials

    ARMYDA-2: Conclusion

    Clopidogrel

    Clopidogrel: Dosage and Administration

    Clopidogrel

    Drug Interactions and Hyporesponse

    Clopidogrel

    Clopidogrel: Warnings

    Clopidogrel

    Clopidogrel: Warnings

    Learning Objectives

    Introduction

    Introduction: Platelet Overview

    Drug Therapy Introduction

    Bleeding

    GP IIb/IIIa Inhibitors

    Mechanism of Action: GP IIb/IIIa Inhibitors

    GP IIb/IIIa Inhibitors

    GP IIb/IIIa Receptor Antagonists

    GP IIb/IIIa Inhibitors

    Approved Indications: Warnings

    GP IIb/IIIa Inhibitors

    Abciximab (ReoPro)

    GP IIb/IIIa Inhibitors

    Eptifibatide (INTEGRILIN)

    GP IIb/IIIa Inhibitors

    Tirofiban (AGGRASTAT)

    Aspirin

    Mechanism of Action: Aspirin as an Inhibitor

    Aspirin

    Mechanism of Action: Aspirin as a Blocker

    Aspirin

    Aspirin: Vascular Indications

    Aspirin

    Aspirin with Ibuprofen (NSAIDs)

    Aspirin

    Aspirin: Warnings

    Dipyridamole

    Dipyridamole: Mechanism of Action

    Dipyridamole

    Approved Indications

    Dipyridamole

    Dipyridamole : Warnings

    Thienopyridines

    Mechanism of Action: Thienopyridines

    Thienopyridines

    Warnings: Thienopyridines

    Thienopyridines

    Ticlopidine (TICLID)

    Thienopyridines

    Clopidogrel (PLAVIX)

    Emerging Therapies

    Phosphodiesterase III Inhibitors: Cilostazol (PLETAL)

    Emerging Therapies

    Therapies on the Horizon

    Introduction

    Introduction: ADP P2Y12 Receptor Antagonists

    Ticlopidine

    Ticlopidine: Mechanism of Action

    Prasugrel

    Prasugrel: Mechanism of Action

    Ticlopidine

    Ticlopidine: Approved Indications

    Ticlopidine

    Ticlopidine: Boxed Warning

    Ticlopidine

    Ticlopidine: Warnings

    Ticlopidine

    Replaced by Clopidogrel

    Clopidogrel Clinical Trials

    CREDO: Conclusion

    Clopidogrel Clinical Trials

    Non-ACS (including Stroke) Studies

    Clopidogrel Clinical Trials

    CARESS Study

    Clopidogrel Clinical Trials

    CARESS: Results

    Clopidogrel Clinical Trials

    MATCH: Conclusion

    Prasugrel

    Prasugrel: Mechanism of Action

    Prasugrel

    Approved Indications

    Prasugrel

    Dosage and Administration

    Prasugrel

    Boxed Warnings

    Prasugrel Clinical Trials

    JUMBO-TIMI 26 Study

    Prasugrel Clinical Trials

    JUMBO TIMI 26: Results

    Prasugrel Clinical Trials

    TRITON-TIMI 38 Clinical Trial

    Prasugrel Clinical Trials

    Objectives: Testing the Hypothesis

    Prasugrel Clinical Trials

    Objectives: Primary Endpoints

    Prasugrel Clinical Trials

    Primary Efficacy and Safety Data

    Prasugrel Clinical Trials

    Primary Efficacy and Safety Data: Net Clinical Benefit and Conclusion

    Prasugrel Clinical Trials

    Stent Thrombosis Sub-Analysis

    Prasugrel Clinical Trials

    Stent Thrombosis Sub-Analysis: Results and Conclusion

    Prasugrel Clinical Trials

    Early and Late Events (Landmark Analysis): Study Design

    Prasugrel Clinical Trials

    Early and Late Events (Landmark Analysis)

    Prasugrel Clinical Trials

    Recurrent Events Data

    Prasugrel Clinical Trials

    STEMI Population Data

    Prasugrel Clinical Trials

    STEMI Population Data: Conclusion

    Prasugrel Clinical Trials

    MI Analysis (Including Universal Definition)

    Prasugrel Clinical Trials

    MI Analysis (Including Universal Definition): Results

    Prasugrel Clinical Trials

    MI Analysis (Including Universal Definition)

    Prasugrel Clinical Trials

    Diabetes Data

    Prasugrel Clinical Trials

    Diabetes Data: Conclusion

    Prasugrel Clinical Trials

    PRINCIPLE-TIMI 44 Study

    Prasugrel Clinical Trials

    PRINCIPLE-TIMI 44: Results and Conclusion

    Thienopyridines

    Differences in Active Metabolite Generation

    Plavix® vs. Effient™

    Comparative PK/PD

    Plavix® vs. Effient™

    Comparative PK/PD: Clinical Implications

    Plavix® vs. Effient™

    Key Differences in Plavix® and Effient™ Label

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

    Contraindications and Boxed Warning

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

    Pharmacokinetics: Absorption

    Rationale For Use of Novel Oral Anticoagulants

    Overview of Anticoagulant Agents

    Standard Agents: Overview

    Fondaparinux

    Standard Agents: Selected Clinical Studies

    Vitamin K Antagonists (VKAs): Warfarin

    Standard Agents: Selected Clinical Studies

    Fondaparinux: Treatment of Deep Vein Thrombosis

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Apixaban: Dosage and Administration

    Introduction

    Introduction

    Rationale For Use of Novel Oral Anticoagulants

    Limitations of Traditional Rapid Acting and Traditional Oral Anticoagulants

    Introduction

    Introduction

    Guidelines for Anticoagulant Therapy

    Anticoagulation Therapy Indications

    Guidelines for Anticoagulant Therapy

    Atrial Fibrillation (AF): Guidelines for Anticoagulation Therapy

    Guidelines for Anticoagulant Therapy

    Venous Thromboembolism (VTE): Treatment Guideline Overview

    Guidelines for Anticoagulant Therapy

    Venous Thromboembolism (VTE): Uncomplicated Treatment

    Guidelines for Anticoagulant Therapy

    Complicated Venous Thromboembolism (VTE) Treatment

    Guidelines for Anticoagulant Therapy

    Venous Thromboembolism (VTE)

    Guidelines for Anticoagulant Therapy

    Venous Thromboembolism (VTE) Treatment Follow-Up and Secondary Prevention: Bridging and Perioperativ...

    Standard Agents: Overview

    Standard Anticoagulants

    Standard Agents: Overview

    Vitamin K Antagonists (VKAs)

    Standard Agents: Overview

    Unfractionated Heparin (UFH)

    Standard Agents: Overview

    Low Molecular Weight Heparin (LMWH)

    Standard Agents: Overview

    Low Molecular Weight Heparin (LMWH): Indications

    Standard Agents: Overview

    Aspirin

    Standard Agents: Selected Clinical Studies

    Selected Clinical Studies

    Standard Agents: Selected Clinical Studies

    Vitamin K Antagonists (VKAs): Warfarin

    Standard Agents: Selected Clinical Studies

    Unfractionated Heparin (UFH) and Low Molecular Weight Heparins (LMWHs)

    Standard Agents: Selected Clinical Studies

    Fondaparinux: Treatment of Pulmonary Embolism

    Standard Agents: Selected Clinical Studies

    Aspirin: Stroke Prevention in Atrial Fibrillation (AF)

    Therapeutic Challenges and Unmet Needs

    Therapeutic Challenges of Antithrombotic Treatment

    Therapeutic Challenges and Unmet Needs

    Vitamin K Antagonists (VKAs): Warfarin

    Therapeutic Challenges and Unmet Needs

    Warfarin: Monitoring and Anticoagulant Reversal

    Therapeutic Challenges and Unmet Needs

    Unfractionated Heparin (UFH)

    Therapeutic Challenges and Unmet Needs

    Low Molecular Weight Heparin (LMWH): Boxed Warning

    Therapeutic Challenges and Unmet Needs

    Low Molecular Weight Heparin (LMWH): Enoxaparin and Dalteparin

    Therapeutic Challenges and Unmet Needs

    Fondaparinux: Boxed Warning, Laboratory Monitoring, and Anticoagulant Reversal

    Therapeutic Challenges and Unmet Needs

    Aspirin: Warnings and Anticoagulant Reversal

    Therapeutic Challenges and Unmet Needs

    Table of Agents

    Rationale For Use of Novel Oral Anticoagulants

    Development and Advantages of Novel Oral Anticoagulants (NOACs)

    Rationale For Use of Novel Oral Anticoagulants

    Complexities of Novel Oral Anticoagulants (NOACs)

    Use of Novel Oral Anticoagulants

    Stroke Prevention in Atrial Fibrillation (AF)

    Use of Novel Oral Anticoagulants

    Stroke Prevention in Atrial Fibrillation (AF): Guidelines

    Administration of Novel Oral Anticoagulants: Overview

    Administration of Novel Oral Anticoagulants: Overview

    Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

    Dabigatran Overview

    Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

    Indications

    Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

    aPTT, Renal Impairment, Special Considerations and Mechanism of Action

    Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

    Clinical Pharmacology

    Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

    Clinical Pharmacology: Pharmacokinetics

    Administration of Novel Oral Anticoagulants: Direct Thrombin Inhibitor: Dabigatran

    Contraindications, Boxed Warning, and Precautions

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

    Overview: Rivaroxaban

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

    Indications, Dosage and Administration

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

    Use in Patients with Renal Impairment

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

    Clinical Pharmacology: Pharmacodynamics, Laboratory Monitoring and Anticoagulant Reversal

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Rivaroxaban

    Warnings, Precautions and Use in Pregnancy

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Overview: Apixaban

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Apixaban: Mechanism of Action

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Clinical Pharmacology: Pharmacodynamics and Anticoagulant Reversal

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Pharmacokinetics: Absorption

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Drug Interaction Studies

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Apixaban: Contraindications and Boxed Warning

    Novel Oral Anticoagulants: Factor Xa Inhibitors: Apixaban

    Apixaban: Warnings, Precautions and Use in Pregnancy

    Summary of Agents

    Summary of Agents

    Current Therapies

    Overview: Current Therapies for MS
    Treatment of Acute Relapses: Severe Relapses: Therapeutic P...

    Emerging Hypotheses on Treatment

    Emerging Hypotheses on Treatment: Myelination-Targeted Antibodies
    Cell Therapy
    Human Stem ...

    view more